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1   Introduction 
 
Paul Ehrlich discovered that methylene blue could stain nerve cells and he promoted the idea 
that low molecular-weight organic compounds could be of value for studying receptors in 
biological systems.1,2 The use of such small molecules instead of genetic mutations to 
establish a link between gene-products and their functions is called chemical genetics. 
Chemical genetics relies on a collection of compounds that are able to change the way 
proteins work directly in real time rather then indirectly by manipulating their genes.  
 
Natural products are known to bind to proteins and may therefore serve as a fruitful source of 
inspiration for the synthesis of compound collections. The natural product quinone family 
contains 1,4-benzoquinone core 1 (Figure 1) and is documented to affect a wide variety of 
biological targets such as enzymes (isomerase, oxidoreductase, flavoenzymes), proteins 
(mitochondrial proteins, microsomal proteins).3,4,5,6 The benzoquinone core is therefore an 
interesting scaffold for the design of a library of chemical probes to be used in chemical 
genetics. 
 
O
O  
                                                                           1 
 
Figure 1: Structure of 1,4-benzoquinone 1 scaffold. 
 
The concepts of chemical genetics will be introduced and background will be provided for the 
use of benzoquinone as a natural and synthetic product. The goals of this thesis will then be 
presented. Finally, the results of the synthetic and biological work will be presented and 
discussed. 
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1.1   Chemical Genetics 
 
In 2004, the sequencing of the human genome was completed.7 There were high expectations 
that this would accelerate our understanding of cellular processes at the molecular level, 
thereby aiding in the development of novel therapies for disease. Alone though, the genetic 
information from the genome sequence is not enough to comprehend intricate biological 
mechanisms: the link between genes and their functions needs to be established. Modern 
genetic methods have made it possible to rapidly identify genes and their mutant alleles by 
simple database operations. Gene cloning and knockout techniques allow the overexpression 
or silencing of proteins in lower organisms such as fruit flies (Drosophila melanogaster), 
zebra fish (Danio rerio) and mice (Mus musculus) to produce observable phenotypical effects. 
Complementarily, human models based on cell lines can also be engineered using molecular 
biological methods. Although developments in genetics have advanced the understanding of 
biological processes, there are still some limitations: the study of essential genes is prevented 
because organisms with mutations in such genes are not viable. Furthermore, genetic 
approaches are not well suited to studying dynamic cellular processes that occur on time 
scales of minutes or seconds.  
 
An alternative approach to linking genes and proteins to their function and phenotypes is 
termed chemical genetics, and uses small molecules to perturb protein networks of biological 
systems.8 It is a multiple step approach that generally begins with the assembly of a collection 
of small molecules, followed by screening of the compounds in a developed assay and finally 
ends with the identification of the modulated target molecule. Like classical genetics, this 
approach attempts to uncover the specific macromolecules (usual proteins) that act as 
regulators of cellular processes. Their functions are subsequently defined using protein 
biochemistry, molecular cell biology and synthetic chemistry. 
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In analogy to genetics, chemical genetics can be divided into two alternative approaches 
namely: forward and reverse chemical genetics (Figure 2).9 These approaches will be briefly 
described in the following sections and will be illustrated with specific examples. 
 
                                              Chemical-genetic approach        
                                     Forward                                  Reverse 
 
Figure 2: Summary of forward and reverse chemical genetics approach to understanding biological systems.7 
 
Forward chemical genetics involves the use of small molecules to screen for a desired 
phenotypical effect on the biological system under investigation. Once a small molecule has 
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been identified, its molecular target needs to be determined. This can be achieved by using 
molecular cell biology and protein biochemistry. 
For example, Mayer et al. used a combination of two phenotypical assays for screening of a 
16,320 member compound library for compounds that affect mitosis.10 One synthetic small 
molecule, monastrol (2), provoked the reorganization of the mitotic spindle (Figure 3). 
 
Figure 3: (A) cell with normal mitotic bipolar spindle; (B) chemical structure of monastrol (2); (C) 
reorganization of mitotic spindle visualized by microscopy.7 
  
The phenotype induced by monastrol had been observed before on inhibition of the mitotic 
kinesin protein Eg5 using anti-Eg5 antibodies.11,12 The effect of monastrol is reversible: 
removing the compound by washing allows cells to move out of mitotic arrest and complete 
mitosis normally. This property was used to study the function of Eg5, which is now an 
established cancer target.13 
 
In reverse chemical genetics, a small molecule is identified against a selected purified protein. 
This molecule is then used to “knockdown” the protein in question at the cellular and 
organismal level.  
For example this approach was used to screen a library of compounds to find a small 
molecule that binds and inactivates the protein MEK1, an enzyme whose activity is needed 
for cell division.14 A potent and selective MEK inhibitor PD184352 (3, Figure 4) was 
identified (50% inhibitory concentration, IC50 17 nM). 
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Figure 4: Chemical Structure of PD184352 (3). 
 
In order to define the function of MEK1 in cell cycle progression, cell growth and cell 
morphology, the effect of PD 184352 was subsequently studied in vivo on mice with colon 
carcinomas of mouse and human origin. These experiments demonstrated that tumor growth 
was inhibited by up to 80 % upon treatment with PD184352. The low toxicity, high potency 
and selectivity made this a promising compound for the treatment of colon cancer. 
Particular advantages of chemical genetics over classical genetics are that temporal control is 
possible as small molecules can be added to the studied systems at any time point during the 
experiment. The effects are also reversible as the compounds can be removed metabolically or 
by washing. In contrast to achieve reversibility in a genetic system, conditional alleles need to 
be introduced and these are normally difficult to generate and control. Another advantage is 
that small molecules have rapid effects, as they are mostly diffusion limited. They can 
therefore be used to observe immediate effects. Furthermore, they can be used to study critical 
genes in developmental stages: whereas a cell knockout may not be viable, it may still be 
possible to study the effects of a knockdown gene product.  
 
However, the main disadvantage is that chemical genetics cannot be applied always straight 
forward. Any gene, in principle, can be specifically manipulated by genetics; chemical 
genetics still needs to find selective small molecules. In forward chemical genetic studies the 
protein-targets still need to be uncovered, which at present is still a challenge. 
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The use of small molecules to study biological systems has a long tradition. The more recent 
systematic use in the context of chemical genetic approach has had a strong impact on fields 
such as signalling15,16, cell morphogenesis17,18, and developmental biology.19 
 
1.1.1   Application Areas of Chemical Genetics 
The use of small molecules to affect biological phenomena, also known as chemical genetics 
has made a significant impact in diverse areas of biology: 
 
Developmental biology 
In developmental biology many studies have involved the use of the chemical genetic 
approach. The advantage of using chemical genetics in this field is that it is possible to control 
the timing of the addition of compounds. An example of the use of chemical genetics in 
developmental biology is the control of the sonic hedgehog (Shh) signalling pathway by the 
alkaloid, cyclopamine. The Shh pathway is implicated in several developmental processes 
including craniofacial development in embryos, organogenesis in the gastrointestinal 
endoderm and limb development. Cyclopamine is a naturally occurring compound isolated 
from Veratrum californicum, the ingestion of which by pregnant sheep has severe effects on 
the developing lamb. Cyclopmanine has been use in the study of Shh signalling underlying 
organogenesis. Lack of Shh signalling in gastrointestinal endoderm results in the formation of 
presumptive pancreatic tissue, whereas adjacent tissue expressing Shh gives rise to the 
stomach and duodenum. Forced expression of Shh pathways was found to block normal 
pancreatic development. This observation led to the hypothesis that the use of cyclopamine to 
inhibit Shh synthesis is critical for rendering gastrointestinal endoderm competent for 
pancreas development.20 
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Signalling   
Kinases 
Kinases are enzymes with a crucial role in transmitting signals between cells and inside cells. 
They are involved in a variety of important cellular functions. Kinases work by 
phospohorylating proteins, which are then activated and able to perform specific functions. 
They control the activation of proteins that cause disease and therefore are prime targets for 
drug development. They play a significant role in nearly all-cellular signalling pathways as 
well as in metabolic disorders, cardiovascular diseases, cancer inflammation, autoimmune 
disorders and neurological diseases. 
 
This large family of homologues enzymes has been difficult to study by either chemical or 
genetic techniques. Because the ATP-binding site is highly conserved throughout the kinase 
family it is difficult to find small molecules of suitable specificity for chemical studies, and 
knockouts fail to account for “compensation”, where other kinases can compensate for the 
absence of a specific kinase during the development process of the organism. By combining 
the features of genetics and chemistry, Shokat et al. developed a general approach for 
regulating with small molecules the kinase enzyme activity in yeast.21,22 Using site-direct 
mutagenesis, they manipulated one of the kinase genes, removing a hydrophobic residue with 
glycine or alanine and creating a new pocket in its ATP-binding site. This did not affect the 
kinase activity (Scheme 1, c), but changes the ability of the enzyme to bind different ligands. 
In this way they found that small molecules that bind in this new site and inhibit the mutant 
protein do not affect any other kinase protein (Scheme 1, b). 
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Scheme 1: Kinase-specific inhibition achieved using chemical genetic reported by Wood et al.13 
a) Wild-type kinases inhibited by a non-specific inhibitor. b) Wild-type kinases are not inhibited by non-specific 
inhibitor analogs containing a sterically bulky fuctional group. c) Engineered kinases show normal kinase 
activity. d) Engineered kinases are inhibited by inhibitor analogs with sterically bulky functional group. e) 
Chemical structure of ATP and the general kinase inhibitor PP1. f) Chemical structure of specific kinase 
inhibitors structure in red indicates modified group. 
 
Transcription 
Chemical genetics has been used in many studies involving the interaction of ligands with 
nucleic acids. One example is the use of chemical genetics to study the role of DNA 
methylation during the cell differentiation process. DNA methylation is implicated in 
epigenetic control of gene expression and is believed to play a significant role in cell lineage 
commitment during development. The role of DNA methylation during the cell differentiation 
process has been demonstrated through use of 5-aza-cytidine (Figure 5b), a nucleotide 
analogue that induces DNA hypomethylation. It has been shown that the adult mesenchynal 
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stem cells isolated from fatty tissue are differentiated into cardiomyocytes after treatment with 
5-azaC.23 The transformed cells exhibited the multinucleated morphology (Figure 5a), 
contracted spontaneously, and express myosin heavy chain, a-actinin (Figure 5c), and 
troponin-I. These results lead to the observation that DNA methylation is involved in 
cardiomycite cell lineage commitment.   
 
 
                        a)                                                       b)                                  c) 
                                         
Figure 5: Treatment of mesenchynal cells with 5-aza-cytidine. a) Cells exhibiting multinucleated morphology 
(arrow). b) Chemical structure of 5-aza-cytidine. c) Cells expressing a-actinin (arrow).23   
         
Antibiotics 
 
The optimism that accompanied the discovery of the first penicillium antibiotics to treat 
Staphylococcal infections in the 1940s has been tempered by the emergence of bacterial 
strains that are resistant to antibiotic treatment. Resistence to antibiotics has been monitored 
to develop rapidly, within one year to one decade of the introduction of the drug to clinical 
use.24 Clinically relevant bacteria are not only characterized today by single drug resistance 
but also by multiple drug resistences, making them a significant public health threats. 
 
Although antibiotics discovery is an example of the succesful mining of natural products for 
therapeutic use, in general the discovery of novel lead structures is becoming more and more 
difficult. Many of the antibiotics in current clinical use are second or third generation 
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modifications of an older scaffold that still bind to the same protein. Therapeutic scaffolds 
have been developed via two alternative routes: from a natural product or from a synthetic 
source. Several natural products have evolved to interact with and to be recognized by targets 
in pathogenic bacteria. They have successfully served as the basis for creating some semi-
synthetic variants of antibiotic natural products currently being used clinically. Antibiotics 
from synthetic sources include the sulfa antibiotics that target folic acid and the 
fluoroquionlone family compounds (Ciprofloxacin) that block DNA gyrase and 
topoisomerase IV. The latest structural class of antibiotics approved for use in this context, 
the oxazolidinones (Linezolid), was introduced 40 years after the discovery of the 
fluoroquinolones. 
 
      Mechanism of action                                              Antibiotic family 
Inhibitors of bacterial cell wall          b-lactams (Penicillium, carbapenem  
              biosynthesis                          cephalosporin; glycopeptides (Vanomicin) 
                                                           Polyketides (tetracyclines); aminoglycosides ; 
Inhibitors of protein biosynthesis      oxazolidinone (Linezolid); ketolides 
                                                           (Erythromycin); macrolides; lincosamides 
Inhibitors of DNA synthesis                        Quinolones (Ciprofloxacin) 
Inhibitors of folic acid synthesis                           Sulfonamides                                                    
 
Table 1: Major families of antibiotics and their mechanism of action. 
 
Not only does there appear to be an innovation gap in the generation of novel antibiotic 
scaffolds, but there are currently only four molecular targets for the main classes of clinically-
used antibiotics (Table 1): bacterial-cell-wall biosynthesis; bacterial protein biosynthesis; 
DNA replication; and folate coenzyme synthesis. New targets may be less susceptible to 
existing mechanisms of bacterial resistance due to a novel mechanism of action. 
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1.1.2   Library Design for Chemical Genetics 
To fully exploit the potential of chemical genetics, it is necessary to have a compound library 
capable of modulating the function of many proteins. Additional properties of the ideal library 
include cell membrane permeability and synthetic accessibility. 
Not only is it currently impossible to generate a library that contains compounds that bind 
selectively to each protein, but for many proteins small molecular ligands have not yet been 
identified. The composition of the library is of great importance, as it should increase the 
probability of finding interesting substances and effects. Fortunately, many natural products 
have been shown to interact with a wide assortment of protein and other biological targets. 
For example, natural products have become effective drugs in a large range of therapeutic 
indications: a few prominent examples are vancomycin, an antibiotic, paclitaxel, a cytostatic 
drug used to treat cancer, and cyclosporine, an immunosuppressive agent. Natural products 
can therefore be considered privileged structures for chemical genetics.25 
 
Currently, there are multiple approaches to designing such libraries: libraries based on natural 
products analogues, libraries based on core scaffolds of natural products and finally libraries 
based on diversity oriented synthesis. It should be mentioned that these categories overlap to 
some extent, and that most synthesized libararies are designed to lie somewhere in between. 
 
Libraries based on natural products analogues 
 
This approach involves use of efficient and reliable methods and multistep sequences for the 
total synthesis of natural products with known biological activity and their analogues on solid 
support and seeks to establish a structure-activity relationship within the compound class. In 
this case the substances are biased towards specific targets. One example of the application of 
this strategy was the synthesis of a 22 analogue library of sarcodictyins (Figure 6). Screening 
of this library lead to the discovery of analogues possessing higher antitumor potencies than 
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those of the parent structure and also established a structure-activity relationship within the 
sarcodictycin-eleutherobin molecular framework.26 
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Figure 6: Selected compounds from a sarcodictyin library based the natural product sarcodictyin (7). 
 
Libraries based on core scaffolds of natural products 
 
The second approach is used primarily to exploit the activity of parent natural products. 
Natural products can be used as biologically validated frameworks upon which to display 
diverse functionalities. Waldmann and co-workers propose that protein domain cores with 
similar three dimensional structures can be clustered in so-called protein similarity clusters 
(PSSC)27 and that this classification can be used as a guiding principle for the selection of 
biologically pre-validated starting points for compound library synthesis. 
According to this principle, ligands for one of the proteins of the cluster can be used as the 
starting point to obtain ligands for other members of the cluster. This approach was used to 
identify inhibitors of the dual-specificity phosphatase Cdc25A 8, acetyl cholinesterase (AchE, 
9) and 11-b-hydroxysteroid dihydrogenase type 1 and 2 (11-b-HSD-1, 10, and 11-b-HSD-2, 
11) from a library of butenolides (Figure 7).30 
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Figure 7: Selected compounds from a butenolide library based on a core scaffold of the natural product Cdc25A 
inhibitor Dysidiolide (8). 
 
Libraries based on diversity oriented synthesis 
 
This approach seeks to exploit the structural characteristics of natural products in a high-
throughput manner: the aims of this strategy are to generate compounds that are easy to 
access, that have plenty of chiral functional groups and are rich in stereochemical information, 
and are skeletally diverse.28 In general, the compounds generated are used as probes for 
understanding cellular processes. In other words, the substances are not aimed at one 
particular target. This strategy was applied to generate a chalcone-based library containing 
74000 members in nine structural variations (Figure 8).29 Scanning of this library gave hits 
with a biological activity over a wide range of therapeutically areas, a result that augurs well 
for discovery screening. 
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Chalcone structure 
 
 
Figure 8: Library based on structure of chalcone (12). 
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1.2   Quinones 
One class of natural products, the 1,4-benzoquinones has an interesting framework and also 
biological activity and are therefore good targets for synthesis of a compound collection for 
the chemical genetics study of their cellular and biological activity. The following sections 
will describe the biology and chemistry of benzoquinone. 
 
1.2.1   Quinones-Containig natural and synthetic products 
The quinone structure (1,4-benzoquinone, Figure 9) was recognized as early as the 1930s as a   
reoccurring structural motif in a variety of synthetic and isolated natural products (Figure 9). 
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Figure 9: Representative natural and synthetic products containig a quinone motif. 
 
This family of compounds has attracted considerable attention for a number of years due to 
their broad range of biological activities.30, 4 A steadily increasing number of quinones are 
being isolated from natural sources (bacteria, fungi, higher plants, animal kingdom, 
arthropods and echinoderms) or are synthesized.3 The biological activity is also remarkably 
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varied, ranging from antibiotic and anticancer activity, antitumor activity, cytotoxicity as well 
as playing a role in cellular metabolism.  
 
Doxorubicin (16, Figure 9) is an antibiotic with antitumor activity from the anthracyclines 
family that is involved in inhibition of DNA, RNA and protein synthesis as well as blockage 
of DNA protein-associated strand breaks and inhibition of DNA repair.31 The target and 
mechanism of action have been actively studied since 196932, 33, and these results have 
implications for the design of novel antitumor antibiotics. 
 
Mitomycin C (17, Figure 9) isolated from S. caespitosis is an antibiotic with high antitumor 
activity and less toxicity than the other mitomycins from this family, which possessess the 
ability to bind to DNA, RNA and protein.34 
 
Triaziquone (18, Figure 9) synthesized first in 195835 is a benzoquinone-containing alkylating 
agent with a variety of anti-tumor activities. This agent presumably produces its antitumor 
effects by alkylation of cellular components36 as well as by inhibition of DNA and RNA 
synthesis.37,38 
 
Diaziquone (19, Figure 9) is a cytostatic compound with a significant activity in a wide 
variety of leukemias, lymphomas and solid tumors.39,40 Its mechanism of action is not fully 
understood but appears to be involved in DNA alkylation, crosslinking and strand breaks 
formation.41 
 
Quinones are also found in the agrochemical field as insecticides, fungicides and herbicides. 
Delan developed at Merck& Co., Inc is a famous fungicide used all over the world today to 
protect fruits, tree and vegetable against pathogenic fungi.  
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Acequinocyl from the acaricide family is a regularly used insecticide which acts as a growth 
inhibitor of many species of agricultural mite at all growth stages as well as an inhibitor of 
mitocondrial respiration.42 
O
O
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S CN
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O
C12H25
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CH3
Delan                                                  Acequinocyl
20 21
 
 
Figure 10: Structure of fungicidal Delan and insecticidal Acequinoscyl. 
 
The interesting biological and structural diversity of this class of substances makes it a 
particularly interesting template for design of compound libraries in the search for small 
molecules that affect cellular signalling pathways. 
 
1.2.2   Synthetic routes to a quinone library 
Solution-Phase Synthesis of a quinone library 
Due the mounting interest in quinones, different libraries were synthesized in solution. 
Waldmann et al.43 reported synthesis in solution of a nakijiquione library using 
isospongiaquinone 22 (synthesized previous) as central intermediate for the synthesis of all 
nakijiquinone analogues. Fifty-six nakijiquinone analogues were synthesized based on the 
strategy below (Scheme 2). Another example is reported by Davioud-Charvet et al.44 They 
synthesized parallel in solution and on solid phase a library of 1,4-naphthoquinones using 
different 1,4-naphthoquinone carboxylic acids intermediates 24, 26, 28 as building blocks 
(Scheme 3). 
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Scheme 2: Solution-phase synthesis of nakijiquinone library. 
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Scheme 3: Solution-phase synthesis of 1,4-naphthoquinones library. 
 
Solid-Phase Synthesis of a quinone library  
A few methods are reported for solid phase quinone synthesis. These methods are 
differentiated from one another by the use of different templates and reaction conditions. 
Armstrong and Tempest45 have introduced squaric acid as a template for the generation of a 
quinone library (Scheme 4), immobilized on solid phase via a Stille reaction or lithium-
halogen-exchange. The resin-bound substrate was used for the synthesis of 1,4-quinone 
derivatives. In the first step, the isopropoxy-group was displaced with primary amines in a 
Michael-type reaction. These compounds were then reacted with lithiated aromatic or 
heteroaromatic compounds or enolethers. After thermolysis and air oxidation in toluene under 
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reflux, substituted 1,4-benzoquinone derivatives were formed and cleaved from the resin with 
20 % TFA/DCM. Unfortunately, the library contains a reduced number of analogues (25) and 
the reaction yields are low, varying between 0-53 %. Davioud-Chavret et al.44 reported 
preparation of a library of 1,4-naphthoquinones containing 1360 analogues. In this case the 
use of 1,4-naphthoquinone carboxylic acid templates provide a library with one variation site. 
Finally, Sharma and Gregory46 reported a 15-member anthraquinone peptide library (Scheme 
5). The use of Leuco-quinizarin as template directly linked to the amino terminus of the 
peptide also only affords in this case a library with one variation site. 
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 Scheme 4: Solid-phase synthesis of quinone library using squaric acid template. 
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Scheme 5: Solid-phase synthesis of anthraquinone peptides library using Leuco-quinizarin template. 
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All of the above-mentioned syntheses demonstrate the feasibility of the quinone and quinone 
precursor as a scaffold for solid phase synthesis.   
 
2   Aim of the Dissertation 
The key to the chemical genetics approach is the availability of a highly diverse library with a 
high percentage of biologically active compounds. The basis and rationale for such a library 
can be taken from natural products, which are themselves biologically pre-validated 
structures47. An example of such a privileged scaffold is the 1,4-benzoquinone ring system. It 
is present in numerous natural products that display diverse biological activities4,37making it a 
particularly suitable template for synthesis of a natural-product-based library for chemical 
genetic studies. 
 
The first aim of this thesis was the development of a rational synthetic route for the synthesis 
of a p-benzoquinone library based on the Michael addition concept. The concept involves 
regioselective addition of different nucleophiles to the quinone ring with formation of the 
hydroquinone as intermediate followed in the next step by oxidation to the corresponding 
quinone. Using the same reaction sequence (addition and oxidation) introduction of different 
substituents in the modifiable positions of the 1,4-benzoquinone ring is conceivable. 
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This approach should allow use of a solid support using parallel synthesis methods, 
simultaneous synthesis of a large number of 1,4-benzoquinone analogues under identical 
reaction conditions in a systematic manner, so that the products of all possible combinations 
of a given set of starting materials (building blocks) will be obtained in one reaction sequence.  
 
To demonstrate the feasibility of this strategy and the potential of 1,4-benzoquinone as a 
scaffold, the synthesis of benzoquinone derivatives should be first undertaken in solution. A 
successful route for the synthesis of model compounds in solution should open up synthetic 
pathways for a large number of benzoquinone analogues on solid phase.  
 
In the light of the documented biological activities of benzoquinone natural products, the next 
objective of this thesis should be the testing of the synthesized benzoquinone library against 
biological targets.  
 
Although, the combinatorial synthesis can be performed also in solution, for synthesis of the 
p-benzoquinone library, solid phase was chosen for several reasons that include easy parallel 
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work-up procedures (filtration), accelerated reactions with higher yields by employing excess 
of reagents and amenability to automation.     
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3   Results and Discussion 
3.1   Synthesis of 2-methoxycarbonyl-1,4-benzoquinone derivatives in solution 
The 2-methoxycarbonyl-1,4-benzoquinone (39) was chosen as building block for the 
synthesis from several reasons. The electron-withdrawing properties of the carbonyl groups 
play an important role for the reactivity and regioselectivity of the benzoquinone ring and as 
consequence position 3 and 5 or 6 of the 2-methoxycarbonyl-1,4-benzoquinone (39) possess 
strong electrophilic character and may be selectively attacked by nucleophilic species. 48,49 An 
additional advantage is that it is easily prepared from commercially available starting 
materials.  
 
In our studies the 1,4-benzoquinone was also tested as building block for the synthesis. 
Unfortunately this proved to be incompatible with our concept. First being a symmetrical 
dienophile offers the possibility of double addition. Second after selective addition of the first 
nucleophile and oxidation to the corresponding benzoquinone, the scaffold was not suitable 
for further diversification following the same route. A reasonable explanation could be that 
after addition of the first nucleophile the quinone ring is electron rich and as result the other 
position from the quinone ring has low electrophilic character.  
 
Prior to the synthesis on solid phase some model reactions were carried out in solution to 
check the feasibility of the Michael addition strategy and the potential of 2-methoxycarbonyl-
1,4-benzoquinone as scaffold (39) as well as different conditions later to be used under solid 
phase conditions. 
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3.1.1   General synthetic plan 
The synthetic route chosen based on Michael addition approach and provides access to 
diverse benzoquinone derivatives.  
 
 
 
Scheme 6: Synthetic strategy towards the synthesis of 2-methoxycarbonyl-1,4-benzoquinone derivatives in 
solution. 
 
In the first step, selective addition of different nucleophiles 40 in the position-3 of the 
benzoquinone 39 take place with formation of the monosubstituted hydroquinone 42 as 
intermediate which is then oxidized to the corresponding benzoquinone 43. In the following 
step the resulted monosubstituted 2-methoxycarbonyl-1,4-benzoquinone (43) is reacted 
through an addition reaction with the second nucleophile 44 with the formation of 
intermediate 45 or disubstituted 2-methoxycarbonyl-1,4-hydroquinone 46 as intermediates. 
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Finally, protection of the resulted intermediates 45 or 46 gave the desired benzoquinone 
derivatives 47 or 48.  
For the synthesis of the diverse 2-methoxycarbonyl-1,4-benzoquinone derivatives, a variety of 
different nucleophiles were tested as starting materials: aliphatic alcohols, secondary and 
primary aromatic amines, aromatic thiols, dienes, amino acids and phenols. 
 
3.2   Addition of the first nucleophile to the 2-methoxycarbonyl-1,4-benzoquinone 
Selective Michael addition of different nucleophile to the 2-methoxycarbonyl-1,4-
benzoquinone ring has been described since long time in the literature.50,51 For the synthesis of 
different monosubstituted benzoquinones, nucleophiles with a low nucleophilicity like 
secondary aromatic amines or alcohols were required. Nucleophiles with a high 
nucleophilicity like aniline react unselectively. 
 
3.2.1   Addition of secondary aromatic amines to 2-methoxycarbonyl-1,4-benzoquinone 
In order to evaluate the possibility to prepare diverse monosubstituted amino benzoquinones 
by Michael addition different secondary aromatic amines were tested as starting material. 
 
 
 
 
Scheme 7: Synthesis of amino benzoquinones. 
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Addition of amine 49 to 2-methoxycarbonyl-1,4-benzoquinone (39) is based on the procedure 
described by P. Müller et al. (Scheme 7).51 The reaction involves in the first step oxidation 
with Ag2O of 2-methoxycarbonyl-1,4-hydroquinone (39) to the corresponding 2-
methoxycarbonyl-1,4-benzoquinone (39) (90% yield) according to the method described by 
K. Brunner.52 2-methoxycarbonyl-1,4-benzoquinone (39) was then reacted with the secondary 
amine 49 for 3 h at room temperature followed by addition of Ag2O in order to oxidize the 
hydroquinone formed in the addition step. Purification by column chromatography gave the 
desired amino benzoquinone 50 a-b. 
 
In contrast to the given procedure, the addition was carried out in toluene, the reaction time 
was 24 h and purification was carried out using toluene/EtOAc as solvent system. The 
structures were determined by NMR and MS measurements. 
 
Following the same procedure, addition of amines possessing an activated CH2 group to the 2-
methoxycarbonyl-1,4-benzoquinone (39) was attempted. Instead of obtaining the 
corresponding monosubstituted amino benzoquinone, the reaction gave unexpected products 
and will be discussed in detail in the following chapter. 
 
3.2.2   Addition of secondary aromatic amines possessing a CH2 group  
In order to test further the potential of 2-methoxycarbonyl-1,4-benzoquinone (39) as scaffold 
and the utility of the Michael addition strategy, addition of other commercially available 
secondary aromatic amines was tested (Scheme 8). 
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Scheme 8:  Synthesis of benzoxazolines derivatives 56 a-d in solution. 
 
Addition of amines 51-54 to the 2-methoxycarbonyl-1,4-benzoquinone (39) gave unexpected 
products: instead of obtaining the expected monosubstituted benzoquinone 55 a novel 
cyclization was encountered, giving benzoxazolines 56 a-d, that was then unable to further 
undergo other transformation. Reactions of this type are known in the literature to take place 
only under specific reaction conditions. For example, M. G. Steinmetz and Y. Chen reported 
formation of benzoxazolines from 2-pyrrolidino-1,4-benzoquinone bearing of phenolate 
leaving groups under photolytic conditions (Scheme 9).53 The mechanism is believed to 
involve existence of a photoinduced electron-transfer step that would be subject to back-
electron transfer (bet) to regenerate the ground state reactant 57. Electron transfer from 
pyrrolidino group to the 1,4-benzoquinone moiety in the lowest triplet excited state generate 
formation of excited state 58 which undergo proton transfer followed by cyclization of 
intermediate 60 to give benzoxazoline 61. 
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Scheme 9: Proposed mechanism for photochemical cyclization of pyrrolidino-substituited 1,4-benzoquinones.53 
 
Another example was reported by Eger et al. in 2006.54 They synthesized different 
dihydrobenzoxazole derivatives (4-amino-emodin derivatives) under strong oxidative 
conditions (Figure 11). 
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Figure 11: Example of cyclic 4-amino-emodin derivatives.54 
 
In the course of this work, the addition of secondary aromatic amines 51-54 to 2-
methoxycarbonyl-1,4-benzoquinone (39) was carried out in toluene, at room temperature and 
using excess of quinone (2 equiv). The yields vary from 6 to 15 % and are similar to those 
reported in the literature.53,54 
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A possible mechanism could involve in the first step selective Michael addition of the amine 
to the quinone ring. In the second step we assume that in this case a second 2-
methoxycarbonyl-1,4-benzoquinone (39) molecule is used for the oxidation of amine moiety 
with formation of  the corresponding benzooxazole (67) as final product through a radical 
mechanism (Scheme 10) . In the literature several examples are known in which oxidation by 
quinones leads to stable free radicals.55,56 
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Scheme 10: Proposed mechanism for the benzoxazolines synthesis. 
 
Unfortunately, the addition of this type of amines to the benzoquinone 39 occurs incomplete 
(unreacted amine could be observed by TLC) and byproducts are formed. Several attempts 
were done in order to improve the reaction yield. Longer reaction time, addition of different 
bases like K2CO3, DIPEA or the use of unpolar solvent like DCM or EtOAc did not provide 
better yield.  
 
Addition of secondary aliphatic amino acids to the 2-methoxycarbonyl-1,4-benzoquinone (39) 
was first tested on solid phase and  will be described in the detail in the Chapter 5.3. 
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3.2.3   Addition of aliphatic alcohols to the 2-methoxycarbonyl-1,4-benzoquinone 
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Scheme 11: Synthesis of 3- alkoxy-1,4-benzoquinones. 
 
 
Addition of alcohols to the 2-methoxycarbonyl-1,4-benzoquinone (39) follows the procedure 
published by O. E. O Hormi and A. M Moilanen.57 The reaction involves addition of the 
alcohol 68 in the presence of MgCl2 as catalyst under N2 atmosphere to the activated 2-
methoxycarbonyl-1,4-benzoquinone (39) with formation of alkoxyhydroquinone which is 
further oxidized by another equivalent of the starting quinone to desired monosubstituted 
benzoquinone 69 a-b. The mechanism involves generation of six-membered chelation ring 
intermediate 70, followed by subsequent nucleophilic attack of the alcohol to the chelated 
quinone 70 (Scheme 12).  
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Scheme 12: Proposed mechanism for the addition of the alcohols to 2-methoxycarbonyl-1,4-benzoquinone  (39). 
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The spectroscopic data (1H NMR, 13C NMR and ESI-MS spectrum) of 69 a-b are in good 
agreement with data published by O. E. O Hormi and A. M Moilanen.57 In the contrast to 
given procedure, purification was carried out in toluene/EtOAc for compound 69a and in 
DCM for compound 69b. 
 
3.3   Addition of the second nucleophile to the monosubstituited 2-metoxycarbonyl-1,4-
bezoquinone 
Because the addition of the first nucleophile to the quinone ring causes low electrophilicity of 
the benzoquinone ring, for the addition of the second nucleophile to the different 
monosubstituted 2-methoxycarbonyl-1,4-benzoquinones, nucleophiles with a high 
nucleophilicity and aromatic character are required. 
 
As addition of nucleophiles to the monosubstituted benzoquinones synthesized in the chapter 
above has until now not been described in the literature, procedures for the addition of other 
nucleophiles to the 1,4-benzoquinones were used as guidelines. 
 
3.3.1   Addition of thiols to the monosubstituted amino benzoquinones 
 
O
O O
OCH3
N
CH3
OCH3
HS
O
O O
OCH3
N
CH3
OCH3S
50a                                                               73                                                                                                     74
2-methoxypyridine/Ag2O
55%
 
 
Scheme 13: Synthesis of 5-Phenylsulfanyl-3-(N-methyl-4`-anisidino)-2-methoxycarbonyl-1,4-benzoquinone (74). 
 
Selective addition of thiophenols to the 2-methoxycarbonyl-1,4-benzoquinone (39) has been 
known for a long time. When the original work of P. Müller et al. 51 is considered, thiophenol 
was reacted with 2-methoxycarbonyl-1,4-benzoquinone (39) in presence of 2-
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methoxypyridine for 3 h, followed by oxidation with Ag2O for another 3 h. This procedure 
leads to the formation of 2-methoxycarbonyl-3-phenylsulfanyl-1,4-benzoquinone. 
In the course of this work, the addition of thiophenol (73) to 3-(N-methyl-4`-anisidino)-2-
methoxycarbonyl-1,4-benzoquinone (50a) was carried out using 2-methoxypyridine for 
deprotonation of thiophenol with concomitant addition of Ag2O (Scheme 13). The reaction 
leads to the 5-phenylsulfanyl-3-(N-methyl-4`-anisidino)-2-methoxycarbonyl-1,4-
benzoquinone (74) in a 55 % yield. 
Following the same reaction procedure, the addition of aliphatic thiols was attempted (Scheme 
14).  
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Scheme 14: Attempt to prepare 5-Butylsulfanyl-3-(N-methyl-4`-anisidino)-2-methoxycarbonyl-1,4-benzoquinone 
(76). 
 
Unfortunately in this case the desired product 76 was not formed as on NMR spectrum only 
the starting material could be detected. 
 
3.3.2   Addition of thiols to the monosubstituted alkoxy benzoquinones 
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Scheme 15: Synthesis of 2-alkoxy-3,6-dihydroxy-4-phenyl-sulfanyl-benzoic ester derivatives (77 a-b). 
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Addition of thiophenol in the presence of 2-methoxypyridine to the monosubstituted 
benzoquinone 69 a-b follows the procedure described by P. Müller et al.51 In contrast to the 
given procedure, a large excess of thiophenol was used in order to achieve completion of the 
reaction. However the reaction did not work in the expected yield, a major byproduct isolated 
was 2-methoxycarbonyl-3-alkoxy-1,4-hydroquinone (78) from the monosubstituted 
benzoquinone 69 a-b. Attempts were made to optimise the yield. Addition of Ag2O in order to 
convert the 2-methoxycarbonyl-3-alkoxy-1,4-hydroquinone (78) back to the starting material 
did not provide a better yield. A longer reaction time was not fruitful either. As usual the 
structure was assigned by NMR spectroscopy and MS spectrometry. 
 
3.3.3   Addition of amines to the monosubstituted amino benzoquinones 
The amines tested were commercially available, and display a range of chemical properties: 
aromatic and aliphatic. 
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Scheme 16: Synthesis of 6-phenyl amino-3-(N-methyl-4`-anisidino)-2-methoxycarbonyl-1,4-benzoquinone (80).  
 
Selective addition of aniline to the monosubstituted benzoquinone 50a has until now not been 
described in the literature. Synthesis of 6-phenyl-amino-3-(N-methyl-4`-anisidino)-2-
methoxycarbonyl-1,4-benzoquinone (80) involves addition of aniline (excess) to the 
intermediate 50a with the formation of 6-phenyl-amino-3-(N-methyl-4`-anisidino)-2-
methoxycarbonyl-1,4-hydroquinone which is unstable at the air and is oxidized to the quinone 
80. A yield of 60 % was obtained after purification. The structure of the product was assigned 
by NMR spectroscopy and MS spectrometry. 
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To evaluate the possibility to prepare other disubstituted amino benzoquinones, addition of 
aliphatic amines depicted below was tested (Scheme 17).  
 
O
O O
OCH3
N
CH3
OCH3
O
O O
OCH3
N
CH3
OCH3
NHR
H2NR
50a                                                        81                                                      82
R= -CH2C6H5
R= -(CH2)3CH3  
 
Scheme 17: Attempts to prepare 6-amino-3-(N-methyl-4`-anisidino)-2-methoxycarbonyl-1,4-benzoquinone (82). 
 
The reactions were performed as described above using excess of amine in order to achieve 
completion of the reaction. But none of them were successful. In both cases a complex 
mixtures of colures products were formed, from which 3-(N-methyl-4`-anisidino)-2-
methoxycarbonyl-1,4-hydroquinone and unreacted amine was isolated along with some 
products impossible to be analysed, probably some decomposition products.  
 
3.3.4   Addition of aromatic amines to the monosubstituted alkoxy benzoquinones 
It was described above that nucleophilic addition of aniline to the monosubstituted amino 
benzoquinones leads to the formation of corresponding diaminobenzoquinones. On that basis 
addition of aniline (79) to the 2-methoxycarbonyl-3-benzyloxy-1,4-benzoquinone (77a) was 
tried. The reaction was carried out in dry toluene and using benzoquinone in excess (Scheme 
18). 
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Scheme 18: Attempt to prepare 6-phenyl amino-3-benzyloxy-2-methoxycarbonyl-1,4-benzoquinone  (84). 
 
However the reaction did not work as expected. After purification by column chromatography 
using DCM as eluent, two fractions were isolated and analysed by NMR spectroscopy. From 
these spectra, it was clear that the disubstituted benzoquinone 84 was formed instead of the 
desired product 83. Actually, there is in the literature precedence that alkoxy substituent from 
benzoquinone ring can be substituted by primary amines (Scheme 19).58 
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Scheme 19: Synthesis of 6-methoxy-2-phenylamino-2-methoxycarbonyl-1,4-benzoquinone (86). 
 
3.3.5   Addition of phenols to the monosubstituted amino benzoquinone 
Following a similar procedure as described by Müller et al.51, in which p-cresol was added to 
the 2-methoxycarbonyl-1,4-benzoquinone, the addition of p-cresol (87) to the 3-(N-methyl-4`-
anisidino)-2-methoxycarbonyl-1,4-benzoquinone (50a) was carried out in dry DCM and in the 
presence of 2-methoxypyridine as base (Scheme 20). After stirring at room temperature for 3 
h, Ag2O was added and the reaction mixture was stirred overnight. From the analysis of the 
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TLC and NMR spectra, it was clear, that desired product 88 was not formed and only starting 
material was detected. Somehow the nucleophilic attack did not take place. The problem of 
this transformation could not be identified. But it might be, that the reactivity of the 
nucleophile was to low and therefore the addition did not take place. 
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Scheme 20: Attempt to prepare 6-methylphenoxy-3-(N-methyl-4`-anisidino)-2-methoxycarbonyl-1,4-
benzoquinone (88). 
 
 
3.3.6   Addition of cyclopentadiene to monosubstituted amino benzoquinones 
To further evaluate the possibility to prepare other disubstituted benzoquinone derivatives, 
cycloaddition to different monosubstituted 1,4-benzoquinones was attempted (Scheme 21) 
using method described by Bäckwall et al.59 as guideline. 
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Scheme 21: Synthesis of 7-(N-methyl-4`-anisidino)-5,8-dioxo-1,4,4a,5,8,8a-hexahydro-1,4-methano-
naphthalene-carboxylic-acid methyl ester (90 a-b). 
 
Compound 90 a-b was synthesized starting from intermediate 50 a-b, which was trapped in a 
Diels-Alder addition with freshly distilled cyclopentadiene (89). Purification by column 
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chromatography gave the desired product 90a, respectively 90b in 98% yield. As usual, the 
structures were elucidated by NMR spectroscopy and MS spectrometry. 
 
3.3.7   Addition of cyclopentadiene to monosubstituted alkoxy benzoquinone 
As in the case described above the main reaction is a Diels-Alder addition between 
cyclopentadiene and 2-methoxycarbonyl-3-benzyloxy-1,4-benzoquinone (77a) (Scheme 22). 
A 95% of desired product 91 was obtained after purification. Structure assignment was 
provided by NMR spectroscopy as well as ESI-MS spectrometry. 
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Scheme 22: Synthesis of 7-benzyloxy-5,8-dioxo-1,4,4a,5,8,8a-hexahydro-1,4-methano-naphtalene-6-carboxylic 
acid methyl ester (91). 
 
3.4   Protection of the disubstituted benzoquinones derivatives 
In order to introduce diversity in the position 2 and 5 of the benzoquinone ring and to prevent 
later decomposition of the quinone derivatives at the cleavage conditions required by solid 
phase, protection of the carbonyl groups from the benzoquinone ring was required and will be 
described in detail in the next Chapters. 
 
3.4.1   Reduction of disubstituted benzoquinone derivatives 
The reduction of 1,4-benzoquinones to hydroquinones has long been known. A commonly 
method uses saturated aqueous solution of  Na2S2O4 in dichloromethane. This method was 
used by Osmo E. O. Hormi and Anu M. Moilanen57 for the reduction of monosubstituted 2-
methoxycarbonyl-1,4-benzoquinone (92). Using their method a 100% yield of disubstituted 
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hydroquinone 93 was obtained (Scheme 23). The structures were determinate using one- and 
two-dimensional NMR spectroscopy and by MS spectra. 
 
 
 
 
 
 
 
 
 
Scheme 23: Reduction of  disubstituted benzoquinone  92. 
 
Reduction of 7-(N-methyl-4`-anisidino)-5,8-dioxo-1,4,4a,5,8,8a-hexahydro-1,4-methano-
naphthalene-carboxylic-acid methyl ester (90a) proved to be challenging. Reduction to the 
corresponding aromatizated diols using NaBH4,60 CeCl37H2O/NaBH461 or Pd/C62 was not 
fruitful due to the instability of the starting material at the reaction conditions (Scheme 24).  
 
 
 
 
Scheme 24: Attempts to reduce 7-(N-methyl-4`-anisidino)-5,8-1,4,4a,5,8,8a-hexahydro-1,4-methano-
naphthalene-carboxylic-acid methyl ester (90a). 
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Therefore an efficient alternative published by J. Meinwald and G. A Wiley63 was considered 
and will be discussed in detail in the next Chapter. 
 
3.4.2   Acetylation of 7-substituted-5,8-dioxo-1,4,4a,5,8,8a-hexahydro-1,4-methano-
naphthalene-6-carboxylic acid methyl ester (93) 
Following the procedure described by Meinwald and Wiley,63 intermediate 93 was reacted 
with Ac2O in the presence of pyridine as solvent (Scheme 25). The reaction proceeds 
smoothly (7 days). After purification the desired unsaturated diacetate was isolated in a yield 
varying between 11 and 98%. A plausible explanation for the lower yield in the case of 
compound 94a and 94b could be that the carbonyl groups are sterical hindered by the 
substituents from the ring. Even, by variation of the reaction conditions (longer reaction time, 
large excess of Ac2O) the yield in these cases could not be improved. The structure was 
assigned using one and two-dimensional NMR spectroscopy as well as MS spectrometry. 
  
 
 
Scheme 25: Acetylation of 7-substituted-5,8-dioxo-1,4,41,5,8,8a-hexahydro-1,4-methano-naphthalene-6-
carboxylic acid methyl ester (93). 
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3.4.3   Alkylation of different disubstituted hydroquinones 
Similar to the reduction, this is a widely used synthetic step. The method used by T. Tori et al
64 was adopted for the protection of hydroquinone 95. Since phenols are relatively acidic, a 
weak base (K2CO3) is used, suffices to deprotonate them. From a variety of possible solvents, 
acetone is used as solvent. The alkylation is carried out with MeI under reflux overnight 
(Scheme 26). A yield varying between 90 and 100% of desired product 96 a-c was obtained. 
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Scheme 26: Alkylation of disubstituted hydroquinone 95. 
  
In the case of 2,5-dihydroxy-6-(N-methyl-4`-anisidino)-3-phenyl amino benzoic acid methyl 
ester (93b) (Scheme 27) alkylation did not work as expected, instead of obtaining the desired 
alkylated product 97, a mixture of  98 and 99 was obtained.  
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Scheme 27: Attempt to protect 2,5-dihydroxy-6-(N-methyl-4`-anisidino)-3-phenyl amino benzoic acid methyl 
ester (93b). 
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A few attempts were to use protecting groups like Fmoc, TBDMS or BnBr, very commonly 
used for protection of hydroquinones (Scheme 28). But none of them were successful. In all 
cases only starting material was recovered. A possible explanation could be that the hydroxyl 
groups are sterically hindered by the substituents from the hydroquinone ring and therefore 
the substitution doesn’t take place. 
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Scheme 28: Attempts to protect 2,5-dihydroxy-6-(N-methyl-4`-anisidino)-3-phenyl amino benzoic acid methyl 
ester (93b). 
 
Therefore the easy and efficient alternative published by G. Höfle et al.65 was chosen as 
alternative. The acetylation was carried out with Ac2O, NEt3 and using DMAP as catalyst 
(Scheme 29). The reaction leads to the desired product (100) in 90% yield. 
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Scheme 29: Acetylation of 2,5-dihydroxy-6-(N-methyl-4`-anisidino)-3-phenyl amino benzoic acid methyl ester 
(93b).  
 
4   Implementation and Optimisation of the Synthesis on Solid Phase 
4.1   Routes for the immobilization of benzoquinone building blocks. 
Different synthetic pathways were explored for the immobilization of the benzoquinone to the 
solid phase. Merrifield resin was chosen as solid support for several reasons. First, it enables 
the release of the target compound (linked as ether or ester) under mild acidic conditions 
(SnCl4), which do not affect its stability. Quinone derivatives are known to be sensitive at 
strong acidic and basic conditions, from this reason the use of other linkers is very limited. 
Second because the linker must be stable at the reaction conditions required for the synthesis 
of desired compounds.   
    
Three approaches will be discussed in the following chapters in order to find synthetic routes 
for the immobilization of benzoquinone scaffold on Merrifield resin.  
First attempt involves the immobilization of the gentisic acid as ester on the resin followed by 
oxidation to give desired benzoquinone building block (strategy A). 
The second attempt is to immobilize 2,5-dimethoxy-benzoyl chloride as amide on Merrifield 
followed by oxidation to give the desired benzoquinone building block (strategy B).  
The last route describes the immobilization of the 2-methoxycarbonyl-1,4-benzoquinone 
using nucleophiles as linker to the solid support (startegy C). 
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 4.1.1   Synthesis of benzoquinone building block onto Merrifield resin using 2,5-dihydroxy 
benzoic intermediate (Strategy A) 
The attempt involves immobilization of the benzoquinone building block as ester to the 
Merrifield resin and is based on the method described in solution by J. Cavallito and J. S 
Buck. 66 
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104                                                                       
 
Scheme 30: Attempt for synthesis of benzoquinone building block onto Merrifield resin using 2,5-dihydroxy 
benzoic intermediate (102). 
The first step occurs with the loading of 2,5-dihydroxy benzoic acid (gentisic acid) (102) onto 
the Merrifield resin 101 as an ester, followed by the oxidation of the resulted intermediate to 
the desired building block, benzoquinone 104. Before performing this approach on solid 
phase, the synthesis was carried out in solution on a identical model system, 2,5-
dihydroxybenzoate (synthesized starting from 2,5-dihydroxybenzoic acid and benzylchloride 
in the presence of K2CO3, 70 °C, 12 h)68, because the monitoring of the intermediate by 
cleavage from the solid phase was not possible in this step from instability reasons (Scheme 
31).  
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Scheme 31: Attempt for oxidation of 2,5-dihydroxybenzoate (106) with DDQ. 
 
Unfortunately several problems prohibit the use of gentisic acid as scaffold for solid phase. 
First, the oxidation step described in the literature uses an insoluble oxidant (MnO2), which is 
not compatible with solid support (just soluble reagents and reactants are compatible with 
solid phase). Second, replacing of the solid oxidant with a soluble oxidant, DDQ (very 
commonly used for hydroquinone oxidations)67, the reaction takes place incomplete and is 
solvent dependent. In protic polar solvents like MeOH, EtOH, iPrOH the oxidation occurs 
with the addition of the solvent molecule to the quinone ring and is incomplete (Figure 12, 
108).  
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Figure 12: 1H-NMR of compound 108. 
 
A possible explanation could be that in the first step the oxidation of the hydroquinone 106 to 
the corresponding benzoquinone take place, followed by a DDQ-catalysed addition of the 
solvent to the benzoquinone with formation of the methoxy-substituted benzoquinone 107. 
There is in the literature precedence that in some cases oxidation of hydroquinone with DDQ 
in the presence of MeOH as solvent leads with the formation of methoxy-substituted 
benzoquinone (Scheme 32).50 
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 Scheme 32: Oxidation of 2-benzyl-1,4-benzoquinone with DDQ using MeOH as solvent. 
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In polar solvents like toluene, dioxane, DMF, the dehydrogenation does not take place as only 
starting material was recovered. There is in the literature precedence that the rate of 
dehydrogenation is higher in polar solvents than in non-polar solvents, but until now does not 
appear to be fully understood in which way the course of the dehydrogenation is influenced 
by the solvent (Scheme 33).50 
 
COCH2CH(CH3)2
OH
CH3
DDQ benzene
COCH2CH(CH3)2
OH
CH3
DDQ
COCH2CH(CH3)2
OH
CHO
no product
CH3OH
111                                                                               112
111  
 
Scheme 33: Effect of the solvent on the oxidation with DDQ.  
 
4.1.2   Synthesis of benzoquinone building block onto Merrifield resin using 2,5-
dimethoxy benzoyl chloride  intermediate (Strategy B) 
Cl
OCH3
OCH3
O
Cl
base
OCH3
OCH3
O O
O
O
oxidation NH
NH
HO NHBoc O NH250% TFA/DCM
   15 min
             113                                                                                                            114                                                115
116                                                                  117
1) NaH, KI, DMF, 50 °C
2)
105
 
 
Scheme 34: Synthesis of benzoquinone building block onto Merrifield resin using 2,5-dimethoxy benzoyl chloride  
intermediate. 
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This attempt involves the use of the 2,5-dimethoxy benzoyl chloride (115) as starting material 
for the synthesis of benzoquinone building block. The first step occurs with the coupling of 
2,5-dimethoxy-benzoyl chloride (synthesized in solution by chlorination of 2,5-dimethoxy-
benzoic acid with oxalyl chloride according to the method describe by Z. Tomaszewski et 
al.68) through nucleophilic substitution to the amino functionalised Merrifield resin 105 
(synthesized by standard methods, NaH, KI, DMF, 50 °C)69, followed by subsequent 
oxidation of the resulted intermediate 116 to the desired building block 117 (Scheme 34).  
Before performing this approach on solid phase, the synthesis was first tested in solution 
(from the same reasons presented in the chapter 4.1.1) using 2,5-dihydroxy-N-phenyl-
benzamide (121) as model system, which was synthesized in three steps according to the 
(Scheme 35). First step involves synthesis of 2,5-dimethoxy benzoyl chloride (115) starting 
from commercially available 2,5-dimethoxy benzoic acid (118) and oxalylchloride (119) 
according to the method described by Tomaszewski et al.68 The resulted intermediate 115 was 
used immediately in the next step without further purification. In the second step 2,5-
dimethoxy benzoyl chloride (115) was reacted with aniline in the presence of K2CO3 for 12 h 
at room temperature according to the method described by Bäckwall et al.59 A 53% yield of 
desired compound 120 was obtained.  The last step involves demethylation of 120 in the 
presence of BBr3 and  -60 °C for 4 h according to the method described by Brimble et al.70 to 
give the desired 121 in 96 % yield.   
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Scheme 35: Attempts for oxidation of 2,5-dihydroxybenzamide  (122). 
 
Different attempts were done in solution in order to oxidize hydroquinone 121 to the desired 
benzoquinone 122. Based on the method described by Parker et al.71 the oxidation of 
hydroquinone 121 was carried out in THF/H2O, at room temperature and with 3 equiv. NaIO4. 
But the desired product 122 could not be isolated. From the analysis of spectra (NMR) only 
some decomposition products were detected. 
 
The oxidation was also performed starting from the intermediate 120 in the presence of ceric 
amonium nitrate, in CH3CN/H2O solvent at room temperature as described Brimble et al.70 
Unfortunately the desired benzoquinone 122 was not formed even after one day. The reaction 
did not proceed at all and only starting material 120 was recovered. 
 
A few attempts were done using solid oxidants as Ag2O52 or PbO272 in order to test if the 
oxidation of the hydroquinone 121 is possible. Unfortunately these were not fruitful either, as 
only starting material was recovered. 
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Scheme 36: Attempts to oxidize 2,5-dihydroxybenzoate (121). 
 
 The problem of this transformation could not been identified. From this reason the strategy 
was not further pursued and a different alternative was chosen. 
 
4.1.3 Immobilization of 2-methoxycarbonyl-1,4-benzoquinone onto Merrifield resin 
(Strategy C) 
 
 
 
 
  
                                                                               
                                                                   
                                                                        
                                                                           
                                                      
 
Scheme 37: Immobilization of 2-methoxycarbonyl-1,4-benzoquinone (38) onto Merrifield resin.  
 
This approach involves in the first step immobilization of different nucleophiles with two 
functionalities on the solid support. The second step occurs with the immobilization of 2-
methoxycarbonyl-1,4-benzoquinone (38) through a Michael addition reaction with the 
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nucleophile linked to the Merrifield resin 123 (as ether or ester) with the formation of 
hydroquinone 124 as intermediate, which can be easily oxidized with DDQ to the 
corresponding benzoquinone 125 (Scheme 37). In this case the nucleophile Nu1 serves as 
linker for the immobilization of quinone scaffold and second as diversity point for library 
synthesis. As nucleophile Nu1 are used reactants with a low nucleophilicity because 
nucleophiles with a high nucleophilicity react unselectively. It must be precise that the 
intermediate 125 was not cleaved from solid phase in this step due to the instability at the 
cleavage conditions. Following this approach the immobilization of the quinone scaffold on 
the solid support was possible and will be discussed in detail in the next chapter.  
 
5   Attempts for the Synthesis of the Benzoquinone Library  
To demonstrate the utility of Michael addition method, and that can be implemented in a 
multistep solid phase synthesis, a challenging multistep synthesis on solid phase was 
attempted. 
5.1   Synthetic plan 
The synthetic route chosen is based on the following solid phase approach.  
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 Scheme 38: Synthetic strategy towards the synthesis of benzoquinone derivatives. 
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The first step occurs with the attachment of Boc protected nucleophiles as ether or ester to the 
Merrifield resin. Next, 2-methoxycarbonyl-1,4-benzoquinone (38)  is reacted through an 
addition reaction with the functionalised resin 123. Hydroquinone 124 is formed as 
intermediate, which in the following step is oxidized with DDQ to the corresponding 
benzoquinone 125, which is then reacted through another addition reaction with the second 
nucleophile with formation after the case of the disubstituted intermediate 126. In the last step 
intermediate 126 is protected. Finally the cleavage is achieved under acidic conditions (SnCl4) 
to the desired compound 128. 
  
By using a solid-phase approach, the time consuming work up steps and the purification of 
synthetic intermediates are eliminated. This is realized by washing the solid-phase with 
different solvents; reactions on the solid-phase can be driven to completion by using a large 
excess of reagents. The cleavage method also ensures the release of the compounds under 
relatively mild conditions, preventing in this way their decomposition.  
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5.2 Attempt for solid phase synthesis of 5,8-diacetoxy-7-(N-methyl-4`-anisidino)-1,4-
dihydro-1,4-methano-naphthalene-6-carboxylic acid methyl ester (134)  
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Scheme 39:  Attempts for solid phase synthesis of 5,8-diacetoxy-7-(N-methyl-4`-anisidino)-1,4-dihydro-1,4-
methano-naphthalene-6-carboxylic acid methyl ester (135). 
 
The solid-phase synthesis of 5,8-diacetoxy-7-(N-methyl-4`-anisidino)-1,4-dihydro-1,4-
methano-naphthalene-6-carboxylic acid methyl ester (135) begins with the loading of  Boc-N-
methylaminophenol (129) (synthesized previous in solution from commercially available N-
methyl-aminophenol according to the method described by Fahey et al.73) on Merrifield resin 
via a substitution reaction (NaH, KI, over night, 60 °C)69 providing 130 in a 93 % yield.  
Loading of the resin 130 was calculated by determination of the chlorine left unreacted on the 
resin using Volhard titration.74 The method involves addition of an excess of standard solution 
of silver nitrate to a solution containing the resin. The excess of silver nitrate is then back 
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triturated with a standard solution of KSCN with ferric iron as indicator in order to calculate 
the amount of chloride that precipitate with the silver in the first step of reaction.  
Following Boc deprotection with 50 % TFA in DCM for 15 minutes, the secondary amine 
130 was reacted with 2-methoxycarbonyl-1,4-benzoquinone (39) through a Michael addition 
reaction to give hydroquinone 131 as intermediate which was oxidized in the next step with 
DDQ  to the quinone  132. Determination of the quinone 132 yield by cleavage was not 
possible from stability reasons, but the violet colour of the resin indicated that reaction took 
place. In the next step the second nucleophile, cyclopentadiene was reacted through a 
cycloaddition reaction with the benzoquinone 132 to afford intermediate 133, which was in 
the following step protected with acetic anhydride in pyridine for 7 days. 
Finally the cleavage from solid-phase was achieved with 10-fold excess of SnCl4 under N2 
atmosphere providing compound 135 in a 25 % yield after purification instead of 
aromatizated diacetate 134. Unfortunately, the acetylating step was not successful. This could 
be due to the solvent, pyridine, which shrinks the resin and diminish, its swelling properties. 
In order to overcome this problem an attempt was made by using mixture of solvents 
pyridine/DCM (1:1). Unfortunately in these conditions the reaction did not take place at all 
even in solution.  
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A representative 1H NMR spectrum of the cleavage product 135 after purification is shown in 
Figure 13: 
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To further demonstrate the utility of this strategy and to test the potential of 2-
methoxycarbonyl-1,4-benzoquinone, addition of secondary aminoacids was attempted and is 
presented in detail in the next Chapter. 
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5.3 Addition of secondary aliphatic amino acids to the 2-methoxycarbonyl-1,4-
benzoquinone 
 
 
Scheme 40: Addition of proline to 2-methoxycarbonyl-1,4-benzoquinone on solid support. 
 
The first step in the synthetic sequence is the immobilization of N-Boc-amino acid 136 to the 
chloromethylated resin 105, which was performed with the appropiate carboxylic acid cesium 
salt at 50 °C in the presence of KI according to the manufactuers instructions described in 
Novabiochem catalogue.69 Then the Boc group was removed by treating the resin with 50 % 
TFA / DCM (1:1 v / v) for 15 minutes followed by the coupling of the proline (138) in the 
presence of DIPEA and TBTU75 to provide dipeptide 139. Analysis of the coupling efficiency 
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by means of bromphenolblue test76, which detects the remaining free amino groups, revealed 
that essentially no underivatized amino groups had remained. In the next step the Fmoc was 
removed with 20 % piperidine/DMF for 20 minutes to give the desired amino free resin 141. 
Loading of the resin was determined by the Fmoc-method77 with spectrometric monitoring of 
the absorbance of dibenzylfulvene-piperidine adduct 140, formed in the cleavage of Fmoc 
group with 20 % piperidine in DMF for 15 minutes (Scheme 40). The resin loadings ranged 
between 63-92 %. 
 
The next step involves addition of 2-methoxycarbonyl-1,4-benzoquinone (39) to peptide 141 
followed by cleavage with SnCl4.78 A 50% yield of 143 was obtained instead of the 
monosubstituted benzoquinone 144. A representative 1H NMR-spectrum of the cleavage 
product 143 directly after workup is shown in Figure 14. 
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In order to compare whether the addition of D- amino acids to the 2-methoxycarbonyl-1,4-
benzoquinone gives a better yield compared with the addition of  L-amino acids, the same 
synthesis was employed first using a mixture of D- and L-proline (1:1) and then using D-
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proline (Scheme 40).  In both cases a similar 40-50% yield was obtained. Structure 
assignment was provided by 1H-NMR spectroscopy as well as by MS spectrometry.  
Following the same standard coupling methods (see Scheme 39), the addition of the secondary 
amino acids, N-Boc-2-piperidine carboxylic acid and 1-Boc-L-azetidine to the 2-
methoxycarbonyl-1,4-benzoquinone scaffold, was attempted (Scheme 41) . 
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Scheme 41: Attempts for the addition of 145 and 146 to the 2-methoxycarbonyl-1,4-benzoquinone (39) on the 
solid support. 
 
However, these attempts proved to be disappointing as only decomposition products were 
identified by NMR spectroscopy and MS spectrometry. The reason could be that products are 
unstable at the cleavage conditions. 
For that reason, the addition step was carried out in solution and the reaction was monitored 
by TLC (Scheme 42). 
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Scheme 42: Attempt for addition of 147 to the 2-methoxycarbonyl-1,4-benzoquinone (39) in solution. 
 
The reaction involves synthesis of the peptide 147 on solid phase using the standard coupling 
conditions presented above (See Scheme 42), followed by cleavage under basic conditions 
(TEA/DMF/MeOH, 50°C).69 The resulted dipeptide 147 was then reacted with the 2-
methoxycarbonyl-1,4-benzoquinone (39) overnight. Unfortunately the reaction proved to be 
disappointing as on TLC only decomposition products could be detected. 
The problem of these transformations could not be identified, but it might be that the desired 
product, formed, probably in low yield was decomposed by the air. There are in the literature 
several examples where benzoxazolines could not be isolated due their instability.53,54 It was 
also reported, that is a differentiation of reactivity of five and six membered ring. It was 
observed, that the formation of the benzoxazoline by photolysis is most efficient with five-
membered pyrrolidinoquinone compared with six member ring where just traces of product 
were detected.79 
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5.4   Synthesis of 5-hydroxy-2-(4-hydroxy-phenyl)-3-phenyl-2,3-dihydro-benzooxazole-4-
carboxylic acid methyl ester (151)  
In order to further test the feasibility of the strategy presented in the Chapter 5.1, the synthesis 
presented in the Scheme 43 was attempted. 
 
 
 
    
  
 
 
 
 
 
 
 
Scheme 43: Attempt for solid phase synthesis of 5-hydroxy-2-(4-hydroxy-phenyl)-3-phenyl-2,3-dihydro-
benzooxazole-4-carboxylic acid methyl ester (151). 
  
The synthesis of 149 occurs in the first step with the loading of Wang resin 148 by 
nucleophilic substitution with benzylamine (79) according to the method described by M. M 
Sim and C. W Phon80 to provide resin 149, which in the next step was reacted with 2-
methoxycarbonyl-1,4-benzoquinone (39) to provide the desired resin 150. Finally the 
cleavage of final compound from the resin was performed under acidic conditions, with 
TMSOTf for 3 h according to the method described by H. Yajima et al.81 to afford 151. 
However the reaction did not work as expected as only traces of the product (1%) was 
isolated along with lots of byproducts. 
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6   Investigation of the Biological Properties of the Benzoquinone Derivatives 
The selection of new scaffolds for the generation of chemical libraries is a crucial step taking 
into account several synthetic requirements, such as compatibility with synthetic technologies 
and biological relevance. The latter presumes the scaffold to be prone to interaction with 
biological target-privileged structure. Scaffold taken from natural products are considered to 
be privileged because of their natural origin. In the next sections the biological properties of 
the synthesized 2-methoxycarbonyl-1,4-benzoquinone derivatives were investigated using a 
variety of biological assays as shown in the (Figure 15). 
 
benzoquinone
  derivatives
    cytotoxicity assay
         MTT assay    check for morphological changes 
                in PtK2 cells
         microbiological assay
        check for antibacterial,
antifugal and antibiotic activity
cellular assay
phenotypical assay
 
 
Figure 15: Screening strategy for benzoquinone derivatives. 
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6.1 Cytotoxicity assay 
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Figure 16: Structure of cytotoxic compounds 56a, 56c, 56d, 94a, 94b, 56b, 100. 
 
When treating cells with compounds, it is necessary to evaluate the effect of the stimuli on the 
proliferative activity and survival/viability of the cell. These parameters can be effectively 
monitored by taking advantage of the cell mitochondrion: mitocondrial dehydrogenases 
reduce tetrazolium compounds inducing colorimetric changes. A commonly used indicator is 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT).82 Living cells convert 
the yellow-colored MTT to a dark blue, water insoluble formazan. For colorimetric 
determination, the MTT-formazan needs to be dissolved in isopropyl alcohol, which is then 
measured at 595 nm. The intensity of the signal correlates with the cell count and metabolic 
activity of the cell.  
 
Figure 17 and 18 show concentration-dependent inhibition curves of the compounds with L-
929 mouse fibroblasts. The metabolic activity of the cells grown in microtiterplates was 
measured by the MTT assay after an incubation period of 5 days. The metabolic activity in 
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each well is dependent on the number of cells that were grown during the 5 days, but also on 
their vitality. The absorbance values measured with compound concentrations between 0.01 
and 400 µg/ml were related to control wells whose activities were set to 100 %.  
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Figure 17: Proliferation of L-929 cells in presence of different concentrations of compounds 94c, 96b, 100, 
94a, 96a, 96c. MTT reduction activity was taken as growth parameter. 
Figure 18:. Proliferation of L-929 cells in presence of different concentrations of compounds 94b, 56d, 
144, 56b, 56a, 56c. MTT reduction activity was taken as growth parameter. 
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From the sigmoid inhibition curves IC50 values down to 7 µmol/L (56a) were obtained and 
listed in Table 2. 
Table 2. Growth inhibitory activity of compounds 96a, 100, 94a, 94b, 96b, 96c, 
94c, 56a, 56b, 56c, 56d, 144 with cultured L-929 mouse fibroblasts. 
Compound IC50 
 [µg/ml] [µmol/L] 
56a 2.3 7 
56c  4.5 11 
56d 5.1 14 
94a 7 16 
94b 15 34 
56b 15 36 
100 31 60 
96a >400   no inhibition 
96b >400 no inhibition 
96c 95 231 
94c 54 128 
144 53 151 
 
Seven compounds (56a, 56c, 56d, 94a, 94b, 56b, 100) were identified to have an effect on the 
cell viability of L-929 mouse fibroblasts cells (see Table 2). 
 
6.2 Phenotypic assays 
The probability of identifying a selective interaction between a compound and a biological 
target increases with the number of compound-target pairs assayed. This is the basic concept 
of empirical high throughput screening (HTS). In the case of a single compound, the number 
of biological targets available for screening determines the success. A cell is a complex 
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biological system containing a huge number of target molecules that are all functionally 
connected: a high content bioassay system. The cell reacts to the action of the compound by 
developing a distinct phenotype. Thus, cell-based phenotypic screening is particularly 
effective in the search for bioactive compounds, although the target is not immediately 
apparent and needs to be identified subsequently. Often, the resulting phenotype is already 
known and can suggest potential target molecules. Therefore, novel compounds should be 
investigated for their phenotypic effects on a series of selected cell types. 
In order to get more information about the mode of action of benzoquinones 
immunofluorescence studies with PtK2 kangaroo rat cells were started. These epithelial-like 
growing cells are very flat and therefore more suitable for conventional microscopic 
observations than the L929 mouse fibroblasts because of fewer problems with depth of focus. 
Derivatives of benzoquinones that show a clear growth inhibition with L929 cells (94a, 100, 
94c, 56a, 56b, 56c) were incubated with the PtK2 cells first over-night. As we observed that 
many compounds acted rather rapidly and induced a cell detachment we reduced the 
incubation time to 4 hours. After fixation the cells were stained for ER and nuclei. 94a, 94c, 
56a, and 56b caused severe changes of the inner structure of the cells. The cells showed large 
vacuoles (Figure 19B, D), deformations of the nuclei (Figure 19C, D), and vesicles in the ER 
(Figure 19C, D; Figure 20A,B). In some cases the ER was almost completely dissolved. 
Especially with 56a (Figure 20A), but also with 56b (Figure 20B), the entire ER network was 
broken down to vesicles only after 4 hours. 100 (Figure 20C) and 56c (Figure 20D) did not 
induce such severe damage of the ER system, only wider meshes in the ER network could be 
observed. The induced changes of the inner membrane structure differ in strength and in 
detail, but taken together it is difficult to decide whether the phenotypes are due to different 
mode of actions. The different phenomena seem to overlap. 
After 4 hours of incubation with 94c, single spots of dense ER were observed aside the 
nucleus, while the rest of the ER network seemed to be unaltered (Figure 21). 
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Immunofluorescence staining with antibodies against gamma-tubulin, a marker protein of 
centrosomes, showed that these spots were not connected to the organelles. Their location was 
independent from these microtubule-organizing centres (Figure 21). 
 
 
 
 
 
 
 
 
 
 
 
 
                                  (A)                                                                   (B) 
 
 
 
 
 
 
 
 
 
 
 
 
                                (C)                                                                                   (D)                                                                                               
 
Figure 19: Influence of benzoquinones on cultured kangaroo rat cells (PtK2). Cells were incubated with 
methanol (A), 94a; 50 µg/ml (B), and 94c; 100 µg/ml (C, D) overnight, fixed and stained for nuclei (blue) and 
ER (green). Treated cells show deformed nuclei, large vacuoles (vac), and ER vesicles (ves). 
ves 
vac 
vac 
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                                (A)                                   (B) 
 
                              (C)                                        (D) 
 
Figure 20: Influence of benzoquinones on cultured kangaroo rat cells (PtK2). Cells were incubated with 56a (A), 
56b (B), 100 (C), and 56c (D) at a concentration of 100 µg/ml for 4 hours (exception 100 over-night), fixed, and 
stained for nuclei (blue) and ER (green). The ER structure of cells treated with 56a and 56b is totally dissolved 
to vesicles 100 and 56c show fewer effects on the ER.. 
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                            (A)                                   (B) 
 
Figure 21: Influence of benzoquinones on cultured kangaroo rat cells (PtK2). Cells were incubated with 94c (A; 
100 µg/ml, B; 66 µg/ml) for 4 hours fixed, and stained for nuclei (blue), ER (green), and centrosomes (red; only 
in B). The photos show single spots of concentrated ER marker protein (p) near the nucleus. These are not 
connected to the centrosomes (c) 
 
Effect on ER structure resembles the action of corallidictyals and siphonodictyols which also 
contain a benzoquinone moiety (Grube, A., Assmann, M., Lichte, E., Sasse, F., Pawlik, J.R. 
M. Köck, New bioactive metabolites from Caribbean sponge Aka coralliphagum, J. Nat. 
Prod., in press). These benzoquinones also induce a vacuolisation of the ER. The vacuoles 
here seem to have a different appearance: they fill the cytoplasm like cushions. A similar 
effect is also observed with flavonols, e.g., myricetin that induces a vesicle formation in the 
ER system (Sasse, personal communication). 
 
 
 
 
 
 
 
 
 
Figure 22: Natural product from Aka coralliphagum 
c 
p 
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Figure 23: Induction of vacuoles within the ER of PtK2 cells by corallidictyal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: Induction of vesicles in the ER system of PtK2 cells by myricetin. 
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Figure 25: PtK2 cells stained for Golgi zone (green) and nuclei (blue). (A) Control cells; (B) Cells that were 
treated with 94c (100 µg/ml) for 4 hours. 
 
Another hypothesis was that the single spots of dense ER induced by 94c are due to changes 
in the Golgi apparatus of the cells. Therefore the Golgi network of treated and untreated PtK2 
cells was labelled by a Golgi zone antibody (Figure 25). The control cells show a Golgi 
network that is concentrated round the nucleus but stretches throughout the cytoplasm. In 
cells treated with 94c the Golgi network has a dramatically altered appearance. There are ring 
like Golgi structures that tightly enfold the nuclei and disordered Golgi structures in the 
cytoplasm. The network seems to be severely damaged, but there are no structures that could 
be connected to the observed ER spots. 
 
6.3 Targeting bacteria and fungi  
The antibacterial, antifugal and antibiotic activity of the twelve benzoquinone derivatives was 
determined for Staphylococcus aureus, Mycobacterium phlei, Micrococcus luteus, E. coli 
tolC, Pseudomonas aeruginosa and Klebsiella pneumoniae, Candida albicans, Hasenula 
anomala, Saccharomyces cerevisiae, Aspergillus fumigatus, Botrytis cinerea and Pythium 
A 
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debaryanum in agar diffusion assays. The MIC values (in the case of Saccharomyces 
cerevisiae) were used as parameter for antibacterial activity and diameter of inhibitons zones 
(in the case of agar diffusion assay) were used as a parameter for the antibiotic, antifugal and 
antibacterial activity. 
Only two of the compounds (56a, 56c) showed antibiotic activities against Staphylococcus 
aureus, Mycobacterium phlei and Pseudomonas aeruginosa.  
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Figure 26: Structure of active compounds 56a and 56c. 
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7   Conclusion 
  
As many benzoquinone-containing natural products have been shown to display diverse and 
interesting biological activities,4,37 the 1,4-benzoquinone moiety was chosen as structural 
scaffold for the design of a natural-product like chemical library for a chemical genetics 
approach. 
 
With the goal to generate a library of p-benzoquinone derivatives on solid phase via a 
sequential Michael addition scheme, first a synthetic route was established in solution in order 
to evaluate the feasibility of this approach and the biological potential of p-benzoquinone. 
 
A set of 11 benzoquinone derivatives was synthesized in solution using 2-methoxycarbonyl-
1,4-benzoquinone as building block (Figure 27). Diversity was introduced in the addition 
steps and in the protection step. The synthesis was effected via Michael addition beginning 
with regioselective addition of the various nucleophiles (Nu1) to the 2-methoxycarbonyl-1,4-
benzoquinone (39) with formation of monosubstituted hydroquinone (42) which was then 
oxidized to the corresponding benzoquinone (43). Using the same reaction sequence, addition 
of the second nucleophile (Nu2) to the monosubstituted 2-methoxycarbonyl-1,4-benzoquinone 
(43) was achieved with the formation of disubstituted compounds (45) or (46). These were 
then protected by acetylation or methylation to provide the desired quinone derivatives (47) or 
(48).  
 
An exception from the general reaction path was observed in the case of secondary aromatic 
amines possessing a CH2 or CH activated group (see Chapter 3.3.2), where after addition 
step, instead of obtaining the corresponding monosubstituted benzoquinone, a novel 
cyclization was encountered, giving benzoxazolines type (56a), (56d) as final product (see 
Figure 27).  
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Figure 27: Summary of the synthesis of 2-methoxycarbonyl-1,4-benzoquinone derivatives in solution. 
 
In order to test diversification possibility of the 2-methoxycarbonyl-1,4-benzoquinone 
scaffold, different classes of nucleophile were tested. Generally, nucleophiles with low 
nucleophilicity and aromatic character were required for monoaddition, where nucleophiles 
with high nucleophilicity yielded the diaddition (see Figure 27).  
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In both cases addition of aliphatic nucleophiles proved to be disappointing ending with the 
mixtures impossible to be analysed. In the last step protection was achieved by acetylation or 
methylation. Overall, the yields varied from 6 % to 65 %.  
The collection of model benzoquinone derivatives synthesized in solution was then used to 
test their biological activity. In the first study, the benzoquinone derivatives were tested for 
cytotoxicity. Seven compounds were cytotoxic beginning at a concentration of 60 mM (Figure 
28). 
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Figure 28: Structure of cytotoxic compounds 56a, 56c, 56d, 94a, 94b, 56b, 100. 
 
In an attempt to look more deeply into the compound-induced morphological effects by 
visualization of intracellular structures and microscopy, PtK2 cells were subject to compound 
treatment followed by staining of nuclei and the endoplasmatic reticulum (ER). Six 
compounds (94a, 100, 94c, 56a, 56b, 56c) showed interesting effects in the morphology of 
the cells. 94a, 100, 56a, and 56b caused severe changes of the inner structure of the cells. The 
cells showed large vacuoles, deformations of the nuclei, and vesicles in the ER. In some cases 
the ER was almost completely dissolved. Especially with 56a, but also with 56b, the entire 
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ER network was broken down to vesicles only after 4 hours. 100 and 56c did not induce such 
severe damage of the ER system, only wider meshes in the ER network could be observed.  
With 94c a patch dense of ER is observed beside the nucleus, while the rest of the ER remains 
unaltered. Immunoflurescence staining with antidodies against gamma-tubulin showed that 
this patches are not connected to the centrosomes, their locations being independent of this 
organelles. The observed effect on the ER structure resembles strongly the action of several 
natural products such as corallidictyals, siphonodictyols and myricetin (flavonol). 
The induced changes in the morphology of the cells differ in strength and in detail for each 
compound. But overall it is difficult to decide whether the phenotypes are due different mode 
of action. The different phenomena seem to overlap. 
 
The benzoquinone derivatives were also tested for bactericidal, fungal and antibiotic activity 
in microbiological assays. None of the benzoquinone derivatives tested show antibacterial or 
fungal activity. Modest antibiotic activity against Staphylococcus aureus, Mycobacterium 
phlei and Pseudomonas aeruginosa was observed for two compounds 56a, 56c (Figure 26).  
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Figure 26: Structure of active compounds 56a and 56c. 
 
After the very promising results with the first model compounds, application of the Michael 
addition concept to a multistep solid-phase synthesis was attempted. After establishing the 
synthetic method on solid phase (Scheme 39), a few quinone derivatives were synthesized in a 
multistep way by using Michael addition as key step. 
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Scheme 38: Implementation of Michael addition concept to solid phase. 
 
The immobilization of 2-methoxycarbonyl-1,4-benzoquione (38) scaffold was achieved via 
Michael addition to the previously functionalized Merifield resin (123) with formation of the 
intermediate (125). After the addition of the second nucleophile, the resulted intermediate 
(126) was protected by acetylation or methylation. Cleavage with SnCl4 furnished the 
benzoquinone derivative (128). An exception from the general strategy must be mentioned in 
the case of formation of benzoxazoline as final product, where the reaction cycle is finish 
after the first addition (see Chapter 5.3 and 5.4).  
 
From all these above reactions it can be concluded that the Michael addition approach has 
been successfully applied in a multistep solid-phase synthesis and the first attempts in order to 
synthesize the benzoquinone library on solid phase have been done. 
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8   Material and Methods 
 
8.1   Synthetic materials and methods 
 
8.1.1   General   
Nuclear Magnetic Resonance Spectroscopy  
1H and 13C NMR spectra were recorded on the following instruments 
             Bruker DPX                      300 MHz, 1H NMR, 75 MHz, 13C NMR 
             Bruker ARX                      400 MHz, 1H NMR, 100 MHz, 13C NMR 
             Bruker Avance DMX        600 MHz, 1H NMR, 151 MHz, 13C NMR 
with tetramethylsilane as the internal reference. The chemical shifts are provided in ppm and 
the coupling constants in Hz. The following abbreviations for multiplicities are used: s, 
singlet; d, doublet; dd, double doublet; t, triplet; q, quadruplet; m, multiplet. 
 
Mass Spectrometry 
The high and low-resolution EI-mass spectra were recorded on a Finnigan MAT MS 95 
(Bremen/Germany). Positive ion electrospray ionisation mass spectra (ESI-MS) were 
recorded on a micromass QTOF 2 mass spectrometer (Micromass, Manchester, UK). The 
isotopic composition of the sample was determinate in the accurate mass mode using 
sacharose ([M + Na] = 365.106 Da) as an internal reference compound. 
 
Thin-Layer Chromatography (TLC) 
Thin-layer chromatography (TLC) plates were obtained from Merck (Silica gel 60, F254). The 
TLCs were visualized by UV light (l = 254 nm, 366 nm) or by staining with iod. The solvent 
system and Rf values are noted for the synthesized compounds. 
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Preparative Layer Chromatography (PLC) 
Preparative layer chromatography plates were obtained from Merck (silica gel 60, F254, 2 mm, 
1 mm and 0.5 mm). 
 
Flash Chromatography 
Flash column chromatography83 was performed using flash silica gel (Merck, Darmstad, 40-
64 mM) with pressure ranging from 0.5-1.0 bar. A 70-100 fold excess of silica gel to the crude 
product was used. 
 
Melting Point 
The melting points were measured with a Büchi 510 melting point apparatus. 
 
Chemicals 
Chemicals were obtained from the following suppliers and used without further purification: 
Aldrich, Fluka, Merck, Lancaster, Novabiochem, and Baker. Dry solvents were purchased 
from Fluka.                        
 
General working procedures (GWP) 
General working procedure 1 (GWP1): Reduction of disubstituited benzoquinones 
To a solution of disubstituited benzoquinone (1 equiv.) in DCM was added a saturated 
solution of Na2S2O4/H2O (10 ml). The mixture was stirred at room temperature until the 
colour of the quinone had disappeared. The organic layer was evaporated under reduced 
pressure. The product was used in the next step without further purification. 
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General working procedure 2 (GWP2): Alkylation of disubstituited hydroquinones 
To a solution of disubstituited hydroquinone (1 equiv.) in acetone (9-17 ml/mmol), was added 
MeI (11-12 equiv.) and K2CO3 (3 equiv.). The reaction mixture was heated under reflux 
overnight. Afterwards the solvent was evaporated and the crude product was purified to give 
the alkylated product. 
 
General working procedure 3 (GWP3): Addition of cyclopentadiene to monosubstituted 
benzoquinones 
To a solution of monosubstituted benzoquinone (1 equiv.) in ether (1.75-4.76 ml/mmol) at 0-5 
°C was added a solution of freshly cracked cyclopentadiene (2.52-6.85 equiv.). The reaction 
mixture was stirred at room temperature for 3-4 h. After completion of the reaction, the 
solvent was evaporated under vacuum. Preparative layer chromatography (DCM/MeOH, 9:1) 
gave the product. 
 
General working procedure 4 (GWP4): Acetylation of 7-substituted-5,8-dioxo-1,4,4a,5,8,8a-
hexahydro-1,4-methano-naphtalene-6-carboxylic acid methyl ester 
To a solution of 7-substituted-5,8-dioxo-1,4,4a,5,8,8a-hexahydro-1,4-methano-naphtalene-6-
carboxylic acid methyl ester (1 equiv.) in pyridine (1.21-1.35 ml/mmol) was added acetic 
anhydride (4-7 equiv.). The homogeneous reaction mixture was allowed to stand at room 
temperature for seven days. After the reaction time has passed, the solvent was evaporated 
under reduced pressure and the resulting mixture separated by preparative layer 
chromatography under conditions described in the individual experimental chapters.  
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General working procedure 5 (GWP5): Addition of alcohols to 2-methoxycarbonyl-1,4-
benzoquinone57 
A mixture of 2-methoxycarbonyl-1,4-benzoquinone (2 equiv.), alcohol (1 equiv.) and MgCl2 
(1 equiv.) in toluene (6.5 ml/mmol) was stirred overnight at room temperature under N2 
atmosphere. Work up was carried out as described for the individual experiments. 
 
General working procedure 6 (GWP6): Addition of thiophenol to monosubstituited 
benzoquinones 
To a solution of of monosubstituited benzoquinone (1 equiv.) in toluene (3.33 ml/mmol) was 
added thiophenol (1.2 equiv.) and a solution of 2-methoxypyridine (3.16 equiv.) in toluene 
(0.53 ml/mmol). The reaction mixture was stirred overnight at room temperature. At the end 
of this time the solvent was evaporated and the residue purified by preparative layer 
chromatography under conditions described in the individual experimental chapters. 
 
General working procedure 7 (GWP7): Synthesis of benzoxazolines 
To a solution of 2-methoxycarbonyl-1,4-benzoquinone (1 equiv.) in toluene (1.66 ml/mmol) 
was added a solution of secondary amine (2 equiv.) in toluene (0.83 ml/mmol) and MgSO4 
(0.84 equiv.). The reaction mixture was stirred at room temperature overnight. Afterwards the 
solvent was evaporated and the residue purified by preparative layer chromatography. 
 
General working procedure 8 (GWP8): Cleavage with SnCl4 78 
To the swollen Merrifield resin (1equiv.) in dry DCM, was added under N2, SnCl4 (10 equiv.). 
The mixture was stirred overnight at room temperature; the excess of SnCl4 was removed by 
extraction with water. Organic layer was evaporated under reduced pressure and purified if 
was necessary. 
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General working procedure 9 (GWP9): Resin loading with Boc-amino acid69  
 
A solution of caesium salt of Boc-amino acid (4.8 equiv., 0.60 mmol, 0.19 g) and KI (0.4 
equiv., 0.05 mmol, 8.30 mg) in 0.80 ml DMF was added to the swollen 
chloromethylpolystyrene resin 77 (0.10 g, loading 1.25 mmol/g, 0.125 mmol, 1 equiv.) which 
was previous washed with dry DMF (3x) before. After heating at 50 °C overnight, the 
solution was filtered off; the resin was washed with DMF, DMF/water, DCM, MeOH, 
followed by Boc deprotection with 50 % TFA/DCM for 15 min and washing with DMF, 
DCM, to provide the corresponding amino acid Merrifield resin. 
 
Preparation of caesium salt of Boc-amino acid: 
To a solution of Boc-amino acid (1mmol/2ml) in EtOH was added water (0.5 ml/mmol). Then 
the pH was adjusted to 7 with 2M aqueous solution of Cs2CO3. Afterwards the solvent was 
evaporated under reduced pressure and the residue was redissolved in dioxane and evaporated 
followed by drying. 
 
General working procedure 10 (GWP10): Loading determination77 
 
Fmoc-amino acid Merrifield resin (1.00 mg) was added in 3 ml 20 % piperidine/DMF 
followed by shaking for 15 min. For reference a second cuvette with 1 ml 20 % piperidine in 
DMF was prepared. Spectrophotometric analysis was carried out at ? = 290 nm (e = 5800 M-1 
cm-1), where the resultant fluvene-piperidine adduct has UV absorption maxima. 
Loading (mmol/g) = Absorption sample / mg of sample x 1.65 
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8.1.2   Compounds from Chapter 3.2 
 
2-Methoxycarbonyl-1,4-benzoquinone 
 
O
O
OCH3
O
876
5
4
2
31
 
                                                                  
                                                                   39 
 
 
To a mixture of methyl-2,5-dihydroxybenzoate 38 (1.00 g, 5.95 mmol), K2CO3 (1.00 g, 3.28 
mmol)  in  50 ml toluene was added Ag2O (3.00 g, 13.00 mmol). The reaction mixture was 
stirred at 50 °C for 30 minutes. After that, the solid was filtered off and the organic phase 
evaporated under reduced pressure to give the title compound in 90 % yield as orange solid, 
which was further use without any purification. 
 
1H-NMR (400 MHz, CDCl3): d = 7.10 (d, 4J (H-3, H-1) = 2.6 Hz, 1H, H-3), 6.93 (d, 3J (H-1, 
H-6) = 8.0 Hz, 4J (H-1, H-3) = 2.6 Hz, 1H, H-1), 6.91 (3J (H-6, H-1) = 8.0 Hz, 1H, H-6), 3.92 
(s, 3H, H-8). 
 
13C-NMR (100 MHz, CDCl3): d = 186.79 (C-5), 182.95 (C-2), 163.16 (C-7), 137.19 (C-4), 
136.96 (C-1*), 136.53 (C-3), 136.17 (C-6*), 53.11 (C-8). 
*These assignments are interchangeable. 
 
HR-EI-MS: m/z (%) = 166.0267 (M+, calcd 166.0266 for C8H6O4). 
 
The spectroscopic data is in agreement with the assigned structure and those reported by 
Brunner K.52 
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 3-(N-Methyl-4`-anisidino)-2-methoxycarbonyl-1,4-benzoquinone 
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                                                                 50a  
   
 
To a solution of 2-methoxycarbonyl-1,4-benzoquinone 39 (0.60 g, 3.61 mmol) in 6 ml toluene 
was added  N-methyl-4-anisidine (0.37 g, 2.73 mmol) and MgSO4 (1.20 g, 10.00 mmol). After 
stirring at room temperature 3 h, Ag2O (2.40 g, 10.35 mmol) was added. Afterwards the 
reaction mixture was stirred at room temperature overnight. Purification was made by flash 
chromatography on silica gel (eluent: toluene/EtOAc, 9:1), followed by crystallization from 
acetone/PEE (1:1), to afford 50a in a 67 % yield as violet crystals.   
Rf = 0.05 (acetone/PEE = 1:1) 
m.p. = 113-114 °C. 
 
1H-NMR (300 MHz, CDCl3): d = 7.04 (d, 3J (H-12, H-11) = 9.0 Hz, 2H, H-12), 6.85 (d, 3J 
(H-11, H-12) = 9.0 Hz, 2H, H-11), 6.66 (d, 3J (H-6, H-1) = 10.2 Hz, 1H, H-6), 6.55 (d, 3J (H-
1, H-6) = 10.2 Hz, 1H, H-1), 3.79 (s, 3H, H-14), 3.56 (s, 3H, H-8), 3.42 (s, 3H, H-9). 
 
13C-NMR (75 MHz, CDCl3): d = 184.75 (C-5), 182.94 (C-2), 165.80 (C-7), 157.97 (C-13), 
148.05 (C-3), 139.76 (C-10), 137.22 (C-6), 134.43 (C-1), 126.31 (C-11), 114.57 (C-12), 
117.81 (C-4), 55.55 (C-14), 52.19 (C-8),  43.89 (C-9).  
 
MS-ESI: m/z (%) = 324 [M+ + Na], 302 [M+ + H]. 
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The spectroscopic data is in agreement with the assigned structure and those reported by 
Müller et al.51 
 
3-(Ethyl-phenyl-amino)-2-methoxycarbonyl-1,4-benzoquinone 
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50b 
                                                             
To a solution of 2-methoxycarbonyl-1,4-benzoquinone 39 (0.60 g, 3.61 mmol) in 6 ml toluene 
was added N-ethylaniline (0.02 g, 0.18 mmol) and  MgSO4 (1.20 g, 9.96 mmol). After 3 h 
stirring at room temperature, Ag2O (0.10 g, 0.43 mmol) was added. The reaction mixture was 
stirred at room temperature overnight. Purification was made by flash chromatography on 
silica gel (eluent: toluene/EtOAc, 9:1) to provide the title compound in 50 % yield as violet 
oil.  
Rf = 0.16 (toluene/EtOAc = 9:1) 
                                                                
1H-NMR (400 MHz, CDCl3): d = 7.33 (t, 3J (H-12, H-13) = 7.6 Hz, 2H, H-12), 7.18 (t, 1H, 
H-14), 7.08 (d, 3J (H-13, H-12) = 7.6 Hz, 2H, H-13), 6.67 (d, 3J(H-1, H-6) = 12.7 Hz, 3J (H-6, 
H-1) = 12.7 Hz, 2H, H-1, H-6), 3.85 (q, 2H, H-9), 3.30 (s, 3H, H-8), 1.21 (t, 3H, H-10).  
 
13C-NMR (100 MHz, CDCl3): d = 185.28 (C-2), 183.05 (C-5), 165.16 (C-7), 148.09 (C-3), 
144.03 (C-11), 137.11 (C-6), 134.78 (C-1), 129.22 (C-13), 125.12 (C-12), 124.19 (C-14), 
120.07 (C-4), 49.36 (C-9), 13.74 (C-10). 
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ESI-MS: m/z (%) = 593 [2M+ + Na], 308 [M+ + Na], 286 [M+ + H]. 
 
HR-EI-MS: m/z (%) = 285.1004 (M+, calcd 285.1001 for C16H15NO4).  
 
5-Hydroxy-2,3-diphenyl-2,3-dihydro-benzooxazole-4-carboxylic acid methyl ester 
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56a 
 
 
Compound 56a was synthesized according to GWP7 starting from 2-methoxycarbonyl-1,4-
benzoquinone 39 (0.12 g, 0.72 mmol) and N-phenyl benzyl amine (0.07 g, 0.36 mmol). The 
crude product was purified by preparative layer chromatography (eluent: toluene/EtOAc, 9:1) 
to provide the title compound in 15 % yield as yellow solid. 
Rf = 0.68 (toluene/EtOAc = 9:1) 
m.p. = 120-121 °C 
 
1H-NMR (300 MHz, CDCl3): d = 10.16 (s, 1H, OH), 7.58 (m, 3J (H-15, H-16) = 5.1 Hz, 2H, 
H-15), 7.41 (m, 4J (H-15, H-17) = 2.1 Hz, 3J (H-16, H-15) = 5.1 Hz, 3H, H-17, H-16), 7.25 (d, 
3J (H-12, H-11) = 8.3 Hz, 2H, H-12), 7.08 (t, 3J (H-13, H-12) = 8.5 Hz, 1H, H-13), 6.92 (d, 
2H, H-11), 6.90 (d, 3J (H-1, H-6) = 8.5 Hz, 1H, H-1), 6.58 (s, 1H, H-9), 6.50 (d, 3J (H-6, H-1) 
= 8.48 Hz, 1H, H-6), 3.31 (s, 3H, H-8). 
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13C-NMR (75 MHz, CDCl3): d = 169.16 (C-7), 155.43 (C-5), 147.13 (C-10), 144.67 (C-2), 
139.40 (C-14), 135.26 (C-3), 129.55 (C-17), 129.15 (C-12), 128.82 (C-16), 126.84 (C-15), 
124.40 (C-13), 120.39 (C-11), 114.78 (C-1), 109.07 (C-6), 102.24 (C-9), 102.07 (C-4), 51.28 
(C-8).  
 
ESI-MS: m/z (%) = 371 [M+ + H  + Na], 370 [M+ + Na], 348 [M+ + H].  
   
EI-MS (70eV): m/z (%) = 347 (55) [M+], 315 (100) [M+, -OCH3, -H  ], 270 (11) [M+ -C6H5], 
238 (38) [M+ -C6H5, -OCH3, -H].  
 
HR-EI-MS: m/z (%) = 347.1163 (M+, calcd 347.1157 for C21H17NO4). 
 
2-(4-Chloro-phenyl)-3-(3,4-dimethyl-phenyl)-5-hydroxy-2,3-dihydro-benzooxazole-4-
carboxylic acid methyl ester 
 
 
 
56b 
 
                                                            
Compound 56b was synthesized according to GWP7 starting from 2-methoxycarbonyl-1,4-
benzoquinone 39 (0.10 g, 0.60 mmol) and 4-chloro-N-(3,4-dimethylphenyl) benzyl amine 
(0.07 g, 0.30 mmol). The crude product was purified by preparative layer chromatography 
(eluent: toluene/EtOAc, 9:1) to provide the title compound in 8 % yield as yellow solid. 
Rf = 0.52 (toluene/EtOAc = 9:1) 
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1H-NMR (300 MHz, CDCl3): d = 10.12 (s, 1H, OH), 7.50 (d, 3J (H-19, H-20) = 8.4 Hz, 2H, 
H-19), 7.40 (d, 3J (H-20, H-19) = 8.4 Hz, 2H, H-20), 6.96 (d, 3J (H-14, H-15) = 8.1 Hz, 1H, 
H-14), 6.85 (d, 3J (H-1, H-6) = 8.4 Hz, 1H, H-1), 6.65 (dd, 3J (H-11, H-15) = 2.2 Hz, 1H, H-
11), 6.62 (d, 3J (H-15, H-14) = 8.1 Hz, 1H, H-15), 6.46 (s, 1H, H-9), 6.45 (d, 3J (H-6, H-1) = 
8.4 Hz, 1H, H-6), 3.31 (s, 3H, H-8), 2.20 (s, 3H, H-17), 2.16 (s, 3H, H-16). 
 
13C-NMR (75 MHz, CDCl3): d = 169.12 (C-7), 155.46 (C-5), 144.95 (C-10), 144.48 (C-2), 
138.15 (C-18), 137.62 (C-12), 135.82 (C-3), 135.41 (C-21), 133.11 (C-13), 130.22 (C-14), 
128.98 (C-20), 128.38 (C-19), 121.93 (C-11), 118.34 (C-15), 114.59 (C-1), 108.88 (C-6), 
102.05 (C-4), 101.77 (C-9), 51.29 (C-8), 19.82 (C-16), 19.17 (C-17). 
 
ESI-MS: m/z (%) = 432 [M+ + Na], 410 [M+ + H].  
 
EI-MS (70eV): m/z (%) = 409 (88) [M+], 377 (100) [M+ -OCH3, -H], 348 (36) [M+ -OCH3, -
2CH3], 266 (76) [M+ -OCH3, -C6H4Cl, -H]. 
 
HR-EI-MS: m/z (%) = 409.1074 (M+, calcd 409.1080 for C23H20ClNO4). 
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5-Hydroxy-2,3-di-p-tolyl-2,3-dihydro-benzooxazole-4-carboxylic acid methyl ester 
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56c 
 
                                                           
Compound 56c was synthesized according to GWP7 starting from 2-methoxycarbonyl-1,4-
benzoquinone 39 (0.10 g, 0.60 mmol) and 4-methoxy-N-(4-methoxyphenyl) benzyl amine 
(0.07 g, 0.39 mmol). The crude product was purified by preparative layer chromatography 
(eluent: toluene/EtOAc, 9:1) to provide the title compound in 13 % yield as yellow oil. 
Rf = 0.52 (toluene/EtOAc = 9:1) 
 
1H-NMR (300 MHz, CDCl3): d = 10.10 (s, 1H, OH), 7.51 (d, 3J (H-16, H-17) = 8.7 Hz, 2H, 
H-16), 6.94 (d, 3J (H-17, H-16) = 8.7 Hz, 2H, H-17), 6.85 (d, 3J (H-1, H-6) = 10.4 Hz, 1H, H-
1), 6.82 (d, 3J (H-11, H-12) = 9.0 Hz, 2H, H-11), 6.77 (d, 3J (H-12, H-11) = 9.0 Hz, 2H, H-
12), 6.42 (d, 3J (H-6, H-1) = 10.4 Hz, 1H, H-6), 6.40 (s, 1H, H-9), 3.82 (s, 3H, H-14*), 3.75 
(s, 3H, H-19*), 3.28 (s, 3H, H-8). 
 
13C-NMR (75 MHz, CDCl3): d = 169.17 (C-7), 160.64 (C-18), 156.94 (C-13), 155.21 (C-5), 
144.53 (C-2), 140.16 (C-3), 137.04 (C-10), 131.40 (C-14), 128.56 (C-16), 123.18 (C-17), 
114.37, 114.09 (C-12*, C-11*, C-1*), 107.80 (C-6), 102.86 (C-9), 100.98 (C-4), 55.52 (C-
14), 55.38 (C-19), 51.31 (C-8).  
* These assignments are interchangeable. 
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ESI-MS: m/z (%) = 837 [M+ + Na], 446 [M+ + K], 430 [M+ + Na], 408 [M+ + H].    
 
HR-EI-MS: m/z (%) = 407.1357 (M+, calcd 407.1368 for C23H21NO6). 
 
5-Hydroxy-2-(4-methoxy-phenyl)-3-phenyl-2,3-dihydro-benzooxazole-4-carboxylic acid 
methyl ester 
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56d 
 
Benzooxazole 56d was synthesized according to GWP7 starting from 2-methoxycarbonyl-1,4-
benzoquinone 39 (0.12 g, 0.72 mmol) and 4-methoxy-N-phenyl benzyl amine (0.07 g, 0.36 
mmol). The crude product was purified by preparative layer chromatography (eluent: 
toluene/EtOAc, 9:1) to provide the title compound in 6 % yield as yellow solid. 
Rf = 0.70 (toluene/EtOAc = 9:1) 
m.p. = 107-108 °C 
 
1H-NMR (300 MHz, CDCl3): d = 10.12 (s, 1H, OH), 7.50 (d, 3J (H-15, H-16) = 8.5 Hz, 2H, 
H-15), 7.23 (dd, 3J (H-12, H-11) = 7.3 Hz, 2H, H-12), 7.06 (t, 1H, H-13), 6.95 (d, 3J (H-16, H-
15) = 8.5 Hz, 2H, H-16), 6.92 (d, 3J (H-11, H-12) = 7.3 Hz, 2H, H-11), 6.88 (d, 3J (H-1, H-6) 
= 8.7 Hz, 1H, H-1), 6.52 (s, 1H, H-9), 6.47 (d, 3J (H-6, H-1) = 8.7 Hz, 1H, H-6), 3.82 (s, 3H, 
H-18), 3.27 (s, 3H, H-8). 
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13C-NMR (75 MHz, CDCl3): d = 169.05 (C-7), 160.52 (C-17), 154.83 (C-5), 146.79 (C-10), 
144.56 (C-2), 135.45 (C-3), 131.48 (C-14), 129.05 (C-12), 128.22 (C-15), 124.38 (C-13), 
120.44 (C-11), 114.46 (C-1), 114.08 (C-16), 108.47 (C-6), 102.08 (C-9), 101.65 (C-4), 55.28 
(C-18), 51.15 (C-8).  
 
ESI-MS: m/z (%) = 401 [M+ + Na], 378 [M+ + H]. 
 
2-Methoxycarbonyl-3-benzyloxy-1,4-benzoquinone 
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69a 
                                                                                         
Benzoquinone 69a was synthesized according to GWP5 starting from 2-methoxycarbonyl-
1,4-benzoquinone 39 (0.50 g, 3.00 mmol) and benzyl alcohol (0.15 g, 1.50 mmol) . The crude 
product was purified by flash chromatography in DCM to provide the title compound in 80 % 
yield as yellow oil. 
Rf  = 0.55 (DCM) 
 
1H-NMR (300 MHz, CDCl3): d = 7.35 (s, 5H, H-11, H-12, H-13), 6.82 (s, 2H, H-1, H-6), 
5.39 (s, 2H, H-9), 3.82 (s, 3H, H-8). 
 
13C-NMR (75 MHz, CDCl3): d = 184.15 (C-2), 182.58 (C-5), 163.39 (C-7), 153.60 (C-3), 
135.26 (C-1), 135.75 (C-10), 134. 77 (C-6), 128.60 (C-12), 128.70 (C-13), 127.96 (C-11), 
122.24 (C-4), 74.60 (C-9), 52.71 (C-8). 
ESI-MS: m/z (%) = 567 [2M+ + Na], 295 [M+ + Na], 273 [M+ + H].     
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HR-EI-MS: m/z (%) = 272.0690 (M+, calcd 272.0685 for C15H12O5). 
  
The spectroscopic data is in agreement with the assigned structure and those reported by 
Hormi et al.57  
         
2-Methoxycarbonyl-3-butoxy-1,4-benzoquinone 
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69b 
 
 
Monosubstituted benzoquinone 69b was synthesized according to GWP5 starting from 2-
methoxycarbonyl-1,4-benzoquinone 39 (3.91 g, 23.50 mmol) and 1-butanol (0.89 ml, 12 
mmol). The crude product was purified by chromatography (eluent: DCM) to provide the title 
compound in 16 % yield as yellow oil.                       
Rf  = 0.64 (DCM) 
 
1H-NMR (300 MHz, CDCl3): d = 6.70 (s, 2H, H-1, H-6), 4.30 (t, 2H, H-9), 3.88 (s, 3H, H-8), 
1.70 (m, 2H, H-10), 1.42 (m, 2H, H-11), 0.90 (t, 3H, H-12). 
 
13C-NMR (75 MHz, CDCl3): d = 184.50 (C-2), 182.34 (C-5), 164.04 (C-7), 153.83 (C-3), 
122.48 (C-1), 120.17 (C-4), 113.41 (C-6), 72.77 (C-9), 52.83 (C-8), 31.71 (C-10), 18.75 (C-
11), 13.59 (C-4). 
   
ESI-MS: m/z (%) = 262 [M+ + H + Na], 261 [M+ + Na], 239 [M+ + H].  
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HR-EI-MS: m/z (%) = 238.0825 (M+, calcd 238.0841 for C12H14O5).  
  
The spectroscopic data is in agreement with the assigned structure and those reported by 
Hormi et al.57 
              
8.1.3   Compounds from Chapter 3.3 
 5-Phenylsulfanyl-3-(N-methyl-4`-anisidino)-2-methoxycarbonyl-1,4-benzoquinone 
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                                                                      74 
 
To a solution of 3-(N-methyl-4`-anisidino)-2-methoxycarbonyl-1,4-benzoquinone 50a (0.15 
g, 0.49 mmol)  in 1.63 ml toluene was added thiophenol 73 (0.06 ml, 0.60 mmol), a solution 
of (0.16 ml, 1.57 mmol) of 2-methoxypyridine in 0.84 ml toluene, Ag2O (0.21 g, 1.23 mmol)  
and MgSO4 (0.16 g, 1.37 mmol). After being stirred at room temperature overnight, the 
reaction solution was concentrated and purified by preparative layer chromatography on 
Merck silica gel (60 F254) plates (eluent: toluene/EtOAc, 9:1) to afford 74 in 55 % as blue 
solid. 
Rf = 0.20 (toluene/EtOAc = 9:1) 
m.p. = 145-146 °C. 
 
1H-NMR (300 MHz, CD3CN): d = 7.56 (m, 5H, H-16, H-17, H-18), 7.17 (d, 3J(H-11, H-12)= 
8.7 Hz, 2H, H-11), 6.85 (d, 3J (H-12, H-11) = 8.7 Hz, 2H, H-12), 5.62 (s, 1H, H-6), 3.81 (s, 
3H, H-14), 3.52 (s, 3H, H-8), 3.35 (s, 3H, H-9). 
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13C-NMR (75 MHz, CD3CN): d = 182.89 (C-5), 180.81 (C-2), 166.29 (C-7), 158.25 (C-13),   
152.15 (C-1), 149.31 (C-3), 141.10 (C-10), 136.37 (C-16), 131.44 (C-15), 131.35 (C-17), 
128.67 (C-18), 127.47 (C-6), 126.36 (C-11), 120.22 (C-4), 115.30 (C-12), 56.18 (C-14),    
52.62 (C-8), 43.62 (C-9).   
 
MS-ESI: m/z (%) = 841 [2M+ + Na], 432 [M+ + Na], 410 [M+]. 
 
HR-ESI-MS: m/z (%) = 410.1060 (M+ + H, calcd 410.1062 for C22H20NO5S).  
 
2-Benzyloxy-3,6-dihydroxy-4-phenyl sulfanyl-benzoic acid methyl ester 
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77a 
        
                                                                   
Disubstituited hydroquinone 77a was synthesized according to GWP6 starting from 
intermediate 69a (0.08 g, 0.30 mmol) and thiophenol (37 µl, 0.36 ml). The crude product was 
purified by preparative layer chromatography on Merck silica gel (60 F254) plates (eluent: 
toluene/EtOAc, 9:1) to provide the title compound in 16 % yield.  
Rf = 0.85 (toluene/EtOAc = 20:1) 
 
1H-NMR (300 MHz, CDCl3): d = 10.67 (s, 1H, HO-5), 7.37-7.42 (m, 10H,  H-11, H-12, H-
13, H-15, H-16, H-17), 6.32 (s, 1H, H-6), 5.66 (s, 1H, HO-2), 4.95 (d, 2H, H-9), 3.95 (s, 3H, 
H-8). 
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13C-NMR (100 MHz, CDCl3): d = 170.11 (C-7), 155.69 (C-5), 144.64 (C-3), 139.71 (C-2), 
136.67 (C-10), 134.25 (C-1), 134.00 (C-15), 130.54 (C-14), 129.04, 129.81 (C-12, C-16), 
128.85, 129.38 (C-17*, C-13*), 128.09 (C-11), 112.25 (C-6), 104.77 (C-4), 76.75 (C-9), 
52.56 (C-8). 
* These assignments are interchangeable. 
 
EI-MS (70 eV): m/z (%) = 382 (16) [M+], 351 (14) [M+ -OCH3], 291 (100) [M+ -CH2C6H5], 
260 (22) [M+ -CH2C6H5, -OCH3], 259 (95) [M+ -CH2C6H5, -OCH3, -H], 91 (90) [CH2C6H5].  
 
HR-EI-MS: m/z (%) = 382.0877 (M+, calcd 382.0874 for C21H18O5S). 
 
2-Butoxy-3,6-dihydroxy-4-phenyl sulfanyl benzoic acid methyl ester 
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  77b 
 
Hydroquinone 77b was synthesized according to GWP6 starting from intermediate 69b (0.02 
g, 0.08 mmol) and thiophenol (9.9 µl, 0.09 mmol). The crude product was purified by 
preparative layer chromatography on Merck silica gel (60 F254) plates (eluent: hexane/EtOAc, 
9:1) to afford the title compound in 29 % yield as yellow solid.  
Rf = 0.56 (hexane/EtOAc = 8:2) 
1H-NMR (300 MHz, CDCl3): d = 10.62 (s, 1H, HO-5), 7.51-7.35 (m, 5H, H-14, H-15, H-16), 
6.22 (s, 1H, H-6), 5.46 (s, 1H, HO-2), 3.99 (s, 3H, H-8), 3.87 (t, 2H, H-9), 1.80 (m, 2H, H-
10), 1.49 (m, 2H, H-11), 0.99 (t, 3H, H-12). 
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 13C-NMR (75 MHz, CDCl3): d = 170.60 (C-7), 155.62 (C-5), 144.73 (C-3), 139.21 (C-2), 
136.00 (C-1), 134.42 (C-14), 130.09 (C-13), 129.83 (C-15), 129.20 (C-16), 111.27 (C-6), 
104.11 (C-4), 75.49 (C-9), 52.55 (C-8), 32.23 (C-10), 19.27 (C-11), 13.95 (C-12). 
 
ESI-MS: m/z (%) = 371 [M+ + Na], 349 [M+ + H].    
                                                                                                                                                                                 
HR-ESI-MS: m/z (%) = 349.1120 (M+, calcd 349.1110 for C18H20O5S).                                                                                                                             
 
 
6-Phenyl amino-3-(N-methyl-4`-anisidino)-2-methoxycarbonyl-1,4-benzoquinone 
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                                                                      80 
 
To a solution of 50a (0.20 g, 0.66 mmol) in 2 ml toluene was added aniline (0.12 ml, 1.32 
mmol). After being stirred at room temperature overnight, the reaction solution was 
concentrated to dryness and the residue purified by preparative layer chromatography on 
Merck silica gel (60 F254) plates (eluent: CH2Cl2/EtOAc, 9:1) to afford 80 in 60 % yield as 
brown solid.   
Rf = 0.81 (DCM/EtOAc = 9:1) 
m.p. =147-148 °C 
 
1H-NMR (300 MHz, CDCl3): d = 7.77 (s, 1H, NH), 7.42 (t, 3J (H-17, H-16) = 8.0 Hz, 3H, H-
17), 7.20 (d, 3J (H-16, H-17) = 8.6 Hz, 2H, H-16), 7.12 (t, 1H, H-18), 7.12 (d, 3J (H-12, H-11) 
= 9.0, 2H, H-12), 6.98 (d, 3J (H-11, H-12) = 9.0, 2H, H-11), 5.98 (s, 1H, H-1), 3.79 (s, 3H, H-
14), 3.56 (s, 3H, H-8), 3.44 (s, 3H, H-9). 
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13C-NMR (100 MHz, CDCl3): d = 182.10 (C-5), 177.7 (C-2), 166.18 (C-7), 158.30 (C-13), 
151.62 (C-3), 144.0 (C-15), 139.80 (C-10), 137.41 (C-6), 129.60 (C-16), 127.0 (C-17), 126.40  
(C-11), 125.61 (C-18), 123.80 (C-4), 114.40 (C-12), 98.90 (C-1), 55.53 (C-14), 51.90 (C-8), 
45.50 (C-9).   
 
EI-MS (70eV): m/z (%) = 392 (100) [M+], 361 (37) [M+ -OCH3]. 
 
MS-ESI: m/z (%) = 807 [2(M+)  + Na], 415 [M+ + Na], 393 [M+ + H].  
 
HR-EI-MS: m/z (%) = 393.1460 (M+ + H, calcd 393.1450 for C22H21N2O5). 
 
7-(N-methyl-4`-anisidino)-5,8-dioxo-1,4,4a,5,8,8a-hexahydro-1,4-methano-naphtalene-
carboxy-lic-acid methyl ester 
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                                                                 90a 
 
 
Intermediate 90a was synthesized according to GWP3 starting from 3-(N-methyl-4`-
anisidino)-2-methoxycarbonyl-1,4-benzoquinone 50a (0.10 g, 0.33 mmol) and 
cyclopentadiene (0.05 g, 0.84 mmol). The crude product was purified by flash 
chromatography (eluent: DCM/MeOH, 9:1) to provide the title compound in 96 % yield as 
orange solid.  
Rf = 0.39 (DCM/MeOH = 9:1) 
m.p. = 55-56 °C 
 
  95
1H-NMR (300 MHz, CDCl3): d = 7.02 (d, 3J (H-11, H-12) = 9.0 Hz, 2H, H-11), 6.84 (d, 3J(H-
12, H-11) = 9.1 Hz, 2H, H-12), 6.21 (dd, 3J (H-16, H-17, H-15) = 5.7 Hz, 1H, H-16), 6.14 (dd, 
3J (H-17, H-16, H-18) = 5.70 Hz, 1H, H-17), 3.80 (s, 3H, H-14), 3.53 (m, 1H, H-15), 3.43 (s, 
3H, H-8),  3.35 (m, 1H, H-18), 3.27 (s, 3H, H-9), 3.31 (dd, 3J (H-1, H-15) = 9.2 Hz, 3J (H-1, 
H-6) = 3.8 Hz, 1H, H-1),  3.20 (dd, 3J (H-6, H-18) = 9.2 Hz, 3J (H-6, H-1) = 3.8 Hz, 1H, H-6), 
1.52 (t, 1H, H-19a), 1.31 (t, 1H, H-19b).   
 
13C-NMR (75 MHz, CDCl3): d = 196.82 (C-2*), 193.24 (C-5*), 166.50 (C-7), 158.27 (C-13),  
154.07 (C-3), 139.10 (C-10), 136.57 (C-16**), 135.31 (C-17**), 126.86 (C-11), 119.60 (C-4), 
114.49 (C-12), 55.54 (C-14), 51.99 (C-8), 50.34 (C-6), 49.77 (C-1), 48.60 (C-19),  47.15,  
47.54 (C-15, C-18),  43.79 (C-9).  
*, ** These assignments are interchangeable. 
 
EI-MS (70 eV): m/z (%) = 367 (67) [M+], 301 (100) [M+ -C5H6]. 
 
HR-EI-MS: m/z (%) = 367.1395 (M+, calcd 367.1419 for C21H21NO5).  
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7-(Ethyl-phenyl-amino)-5,8-dioxo-1,4,4a,5,8,8a-hexahydro-1,4-methano-naphtalene-6-
carboxylic acid methyl ester 
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Compound 90b was synthesized according to GWP3 starting from intermediate 50b (0.06 g, 
0.21 mmol) and cyclopentadiene (0.09 g, 1.44 mmol). The crude product was purified by 
preparative layer chromatography (eluent: DCM/MeOH, 9:1) to provide the title compound in 
98 % yield as white oil. 
Rf = 0.86 (DCM/MeOH = 9:1) 
                                                                   
1H-NMR (300 MHz, CDCl3): d = 7.32 (t, 3J (H-12, H-13) = 8.5 Hz, 2H, H-12), 7.20 (t, 3J (H-
14, H-13) = 7.4 Hz, 1H, H-14), 7.05 (d, 3J (H-13, H-12) = 8.5 Hz, 2H, H-13), 6.22-6.20 (m, 3J 
(H-16, H-17, H-15) = 5.7 Hz, 3J (H-17, H-16, H-18) = 5.7 Hz, H-16,H-17), 3.73 (q, 2H, H-9), 
3.51 (m, 1H, H-15),  3.44 (m, 1H, H-18), 3.35 (m, 3J (H-1, H-15) = 9.2 Hz, 3J (H-1, H-6) = 
3.8 Hz, 3J(H-6, H-18) = 9.2 Hz, 3J (H-6, H-1) = 3.8 Hz, 2H, H-1, H-6), 3.21 (s, 3H, H-8), 1.61 
(t, 1H, H-19a), 1.40 (t, 1H, H-19b), 1.23 (t, 3H, H-10).   
 
13C-NMR (75 MHz, CDCl3): d = 197.35 (C-2), 193.29 (C-5), 165.88 (C-7), 153.75 (C-3),  
143.42 (C-11), 136.49 (C-16**), 135.19 (C-17**), 129.15 (C-12***), 126.61 (C-14), 126.32 
(C-13***), 121.74 (C-4), 52.59 (C-8), 50.16 (C-6), 49.65 (C-1), 49.56 (C-9), 48.65 (C-19),  
47.69 (C-15****),  47.43 (C-18****), 13.89 (C-10). 
*, **, ***, **** These assignments are interchangeable. 
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ESI-MS: m/z (%) = 725 [2M+ + Na], 374 [M+ + Na], 352 [M+ + H]. 
 
HR-EI-MS: m/z (%) = 351.1475 (M+, calcd 351.1470 for C21H21NO4).  
 
7-Benzyloxy-5,8-dioxo-1,4,4a,5,8,8a-hexahydro-1,4-methano-naphtalene-6-carboxylic 
acid  methyl ester 
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                                                                    91 
 
Intermediate 91 was synthesized according to GWP3 starting from monosubstituited 
benzoquinone 77a (0.15 g, 0.57 mmol) and cyclopentadiene (0.09 g, 1.44 mmol). The crude 
product was purified by preparative layer chromatography on Merck silica gel (60 F254) plates 
(eluent: DCM/MeOH, 9:1) to provide the title compound in 95 % yield as yellow oil. 
Rf = 0.56 (DCM/MeOH = 9:1) 
 
1H-NMR (300 MHz, CDCl3): d = 7.21-7.40 (m, 5H, H-11, H-12, H-13), 6.11 (m, 3J (H-15, H-
16, H-14) = 5.1 Hz, 1H, H-15), 5.66 (m, 3J (H-16, H-17, H-15) = 5.1 Hz, 1H, H-16), 5.45-
5.28 (s, 2H, H-9), 3.76 (s, 3H, H-8), 3.49-3.30 (m, 2H, H-14, H-17), 3.20 (q, 1H, H-6), 3.12 
(q, 1H, H-1), 1.49 (d, 1H, H-18a), 1.25 (t, 1H, H-18b).   
 
13C-NMR (75 MHz, CDCl3): d = 195.19 (C-2*), 194.93 (C-5*), 163.88 (C-7), 158.38 (C-3),  
135.73 (C-10), 135.51 (C-15**), 134.64 (C-16**), 129.64 (C-4), 128.51 (C-11), 128.46 (C-
12***), 128.05 (C-13***), 73.92 (C-9), 52.41 (C-8), 49.36 (C-17****), 48.98 (C-18),  48.88 
(C-14****),  48.76 (C-1),  48.67 (C-6).  
  98
*, **, ***, **** These assignments are interchangeable. 
ESI-MS: m/z (%) = 699 [2M+ + Na], 362 [M+ + H + Na], 361 [M+ + Na]. 
 
HR-EI-MS: m/z (%) 338.1140 (M+, calcd 367.1154 for C20H18O5).  
 
8.1.4   Compounds from Chapter 3.4 
3,6-Dihydroxy-2-(N-methyl-4`-anisidino)-4-phenyl sulfanyl-benzoic acid methyl ester  
 
1617
18 S
O
OCH3
N
CH3
OCH3
OH
OH
1
2
3
4
5
6
7 8
9
10
11 12
13
14
15
 
 
                                                                      93a 
 
5-Phenyl-3-(N-methyl-4`-anisidino)-2-methoxycarbonyl-1,4-benzoquinone 92  was reduced 
with saturated solution of Na2S2O4/H2O to hydroquinone 93a according  to GWP1. A 100 % 
yield of the title compound was obtained as yellow solid. 
 
1H-NMR (300 MHz, CD3CN): d = 10.65 (s, 1H, HO-5), 7.59 (t, 1H, H-18), 7.42 (d, 3J (H-17, 
H-16) = 8.0 Hz, 2H, H-17), 7.46 (m, 3J (H-16, H-17) = 8.0 Hz, 2H, H-16), 6.78 (d, 3J (H-11, 
H-12) = 9.0 Hz, 2H, H-11), 6.53 (d, 3J (H-12, H-11) = 9.0 Hz, 2H, H-12), 6.42 (s,1H, HO-2), 
6.31 (s, 1H, H-6), 3.73 (s, 3H, H-14), 3.56 (s, 3H, H-8), 3.21 (s, 3H, H-9). 
 
13C-NMR (75 MHz, CD3CN): d = 169.82 (C-7), 156.67 (C-5), 152.80 (C-13), 143.65 (C-2), 
143.00 (C-10), 135.74 (C-1), 135.22 (C-16), 131.73 (C-3), 129.97 (C-17), 129.78 (C-18),   
129.55 (C-15), 114.63 (C-12), 114.17 (C-11), 113.89 (C-6), 106.87 (C-4), 55.78 (C-14), 52.25 
(C-8), 38.65 (C-9). 
 
  99
EI-MS (70 eV): m/z (%) = 411 (100) [M+], 396 (8) [M+ -CH3], 302 (6) [M+ -SC6H5]. 
HR-EI-MS: m/z (%) = 411.1090 (M+, calcd 411.1140 for C22H21NO5S). 
 
2,5-Dihydroxy-6-(N-methyl-4`-anisidino)-3-phenyl amino benzoic acid methyl ester 
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6-Phenyl amino-3-(N-methyl-4`-anisidino)-2-methoxycarbonyl-1,4-benzoquinone 92 (0.02 g, 
0.05 mmol) was reduced with saturated solution of  Na2S2O4/H2O to the hydroquinone 93b 
according to GWP1. A 100 % of the title compound was obtained as yellow solid. 
 
1H-NMR (300 MHz, CDCl3): d = 11.15 (s, 1H, HO-5), 7.35 (t, 3J ( H-17, H-16) = 8.0 Hz, 2H, 
H-17), 7.22 (d, 3J ( H-16, H-17) = 8.0 Hz, 2H, H-16), 7.03 (t, 1H, H-18), 6.78 (d, 3J (H-12, H-
11) = 9.0 Hz, 2H, H-12), 6.51 (d, 3J (H-11, H-12) = 9.0 Hz, 2H, H-11), 6.41 (s, 1H, H-1), 6.10 
(s, 1H, HO-2), 3.78 (s, 3H, H-14), 3.61 (s, 3H, H-8), 3.12 (s, 3H, H-9). 
 
13C-NMR (75 MHz, CDCl3): d = 170.65 (C-7), 152.38 (C-13), 147.40 (C-2), 145.83 (C-5), 
143.92 (C-10), 141.26 (C-15), 133.72 (C-6), 129.49 (C-16), 122.55 (C-18), 121.84 (C-3), 
120.19 (C-17), 114.72 (C-12*), 113.72 (C-11*), 109.15 (C-4), 104.86 (C-1), 55.79 (C-14), 
52.47 (C-8), 39.07 (C-9).   
** These assignments are interchangeable. 
   
ESI-MS: m/z (%) = 417 [M+ + Na], 395 [M+ + H]. 
 
HR-EI-MS: m/z (%) = 394.1429 (M+, calcd 394.1528 for C22H22N2O5). 
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5,8-Diacetoxy-7-(N-methyl-4`-anisidino)-4-dihydro-1,4-methano-naphtalene-6-carboxy-
lic acid methyl ester 
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Compound 94a was synthesized according to GWP4 starting from 7-(N-methyl-4`-anisidino)-
5,8-dioxo-1,4,4a,5,8,8a-hexahydro-1,4-methano-naphtalene-6-carboxylic acid methyl ester 93 
(0.10 g, 0.28 mmol) and acetic anhydride (0.11 ml, 1.23 mmol). The crude product was 
purified by preparative layer chromatography on Merck silica gel (60 F254) plates (eluent: 
DCM/EtOAc, 9:1) to afford the title compound in 53 % yield as yellow solid. 
Rf = 0.71 (DCM/EtOAc = 9:1) 
m.p. = 73-74 °C 
 
1H-NMR (400 MHz, CDCl3): d = 6.81 (dd, 3J (H-17, H-16, H-18) = 5.0 Hz, 1H, H-17*), 6.77 
(dd, 3J (H-16, H-17, H-15) = 5.0 Hz 1H, H-16*),  6.71 (d, 3J (H-12, H-11) = 9.0 Hz, 2H, H-
12), 6.56 (d, 3J (H-11, H-12) = 9.0 Hz, 2H, H-11), 3.89 (s, 1H, H-18**),  3.85 (s, 1H, H-
15**), 3.71 (s, 3H, H-14), 3.57 (s, 3H, H-8), 3.07 (s, 3H, H-9), 2.28 (m, 1H, H-19a***), 2.26 
(s, 3H, H-20****), 2.21 (m, 1H, H-19b***), 1.96 (s, 3H, H-23****).   
*, **, ***, **** These assignments are interchangeable. 
 
13C-NMR (100 MHz, CDCl3): d = 168.49 (C-21*), 168.33 (C-22*), 165.60 (C-7), 152.57 (C-
13), 148.76 (C-1**), 143.38 (C-6**), 142.96 (C-10), 142.49 (C-16***), 142.14 (C-17***), 
  101
140.51 (C-5), 139.37 (C-2), 137.42 (C-3), 124.54 (C-4), 115.21 (C-11****), 114.38 (C-
12****), 67.87 (C-19), 55.75 (C-14), 52.18 (C-8), 48.64 (C-15*****), 48.21 (C-18*****), 
39.53 (C-9), 20.58 (C-20******), 20.29 (C-23******).  
*, **, ***, ****, *****, ****** These assignments are interchangeable. 
 
EI-MS (70 eV): m/z (%) = 451 (100) [M+], 408 (13) [M+-COCH3].    
          
HR-EI-MS: m/z (%) = 451.1620 (M+, calcd 451.1631 for C25H25NO7). 
 
5,8-Diacetoxy-7-(ethyl-phenyl-amino)-1,4-dihydro-1,4-methano-naphtalene-6-carboxylic 
acid methyl ester 
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Compound 94b was synthesized according to GWP4 starting from intermediate 93 (0.06 g, 
0.17 mmol) and acetic anhydride (0.11 ml, 1.23 mmol). The crude product was purified by 
flash chromatography (eluent: toluene/EtOAc, 9:1) to provide the title compound in 11 % 
yield as pale yellow oil. 
Rf = 0.32 (toluene/EtOAc = 9:1) 
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1H-NMR (300 MHz, CDCl3): d = 7.12 (t, 3J (H-13, H-12) = 8.9 Hz, 2H, H-13), 6.83 (m, 3J 
(H-16, H-17, H-15) = 5.3 Hz, H-16), 6.80 (m, 3J (H-17, H-18, H-15) = 5.3 Hz, 1H, H-17) 6.72 
(t, 1H, H-14), 6.60 (d, 3J (H-12, H-13)= 8.9 Hz, 2H, H-12), 3.91 (m, 1H, H-15), 3.81 (m, 1H, 
H-18), 3.60 (s, 3H, H-8), 3.59 (q, 2H, H-9), 2.29 (s, 3H, H-20*), 2.22 (m, 1H, H-19a), 2.20 
(m, 1H, H-19b), 1.91 (s, 3H, H-23*), 1.20 (t, 3H, H-10).  
 
13C-NMR (75 MHz, CDCl3): d = 168.44 (C-22*), 168.11 (C-21*), 165.69 (C-7), 148.84 (C-
1**),  147.65 (C-11), 143.93 (C-6**), 142.39 (C-16***), 142.23 (C-17***), 140.56 (C-5), 
139.26 (C-2), 135.95 (C-3), 128.74 (C-13), 125.43 (C-4), 118.02 (C-12), 114.58 (C-14),  
52.22 (C-8), 48.97 (C-15****), 48.27 (C-18****), 46.79 (C-9), 20.61 (C-23*****),  20.28 
(C-20*****),  12.82 (C-10). 
*, **, ***, ****, ***** These assignments are interchangeable. 
 
ESI-MS: m/z (%) = 458 [M++ Na], 436 [M+ + H]. 
 
HR-ESI-MS: m/z (%) = 436.1770 (M+ + H, calcd 436.1760 for C25H26NO6).  
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5,8-Diacetoxy-7-benzyloxy-1,4-dihydro-1,4-methano-naphtalene-6-carboxylic acid  
methyl ester  
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The title compound 94c was synthesized according to GWP4 from intermediate 93 (0.10 g, 
0.29 mmol) and acetic anhydride (0.11 ml, 1.23 mmol). The crude product was purified by 
preparative layer chromatography on Merck silica gel (60 F254) plates (eluent: DCM/EtOAc, 
9:1) to provide the title compound in 96 % yield as yellow oil. 
Rf = 0.90 (DCM/EtOAc = 9:1) 
 
1H-NMR (300 MHz, CDCl3): d = 7.30 (m, 5H, H-11, H-12, H-13), 6.81 (m, 3J (H-15, H-16, 
H-14) = 5.1 Hz, 1H, H-15*), 6.76 (m, 3J (H-16, H-17, H-15) = 5.1 Hz, 1H, H-16*), 4.96 (s, 
2H, H-9), 3.88 (m, 2H, H-17**, H-14**), 3.76 (s, 3H, H-8), 2.28 (s, 3H, H-22***), 2.21 (m, 
2H, H-18), 2.17 (s, 3H, H-19***).   
*, **, *** These assignments are interchangeable. 
 
13C-NMR (75 MHz, CDCl3): d = 168.57 (C-21*), 168.35 (C-20*), 164.81 (C-7), 148.65 (C-
6**), 147.47 (C-3), 142.67 (C-15***), 141.72 (C-16***), 140.58 (C-1**), 139.02 (C-5****), 
137.17 (C-10), 136.49 (C-2****), 128.37 (C-12******), 127.94 (C-13), 127.57 (C-11*****), 
118.38 (C-4), 76.95 (C-9), 67.78 (C-18), 52.24 (C-8), 48.43 (C-17******), 47.82 (C-
14******), 20.54 (C-19*******), 20.41 (C-22*******).  
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*, **, ***, ****, *****, ******, ******* These assignments are interchangeable. 
 
EI-MS (70 eV): m/z (%) = 422 (100) [M+], 391 (17) [M+ -OCH3], 91 (84) [CH2C6H5].   
      
HR-EI-MS: m/z (%) = 422.1355 (M+, calcd 422.1365 for C24H22O7). 
 
3,6-Dimethoxy-2-(N-methyl-4`-anisidino)-4-phenyl sulfanyl benzoic acid methyl ester 
synthesis 
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The title compound 96a was synthesized according to GWP2 starting from 3,6-dihydroxy-2-
(N-methyl-4`-anisidino)-4-phenyl sulfanyl benzoic acid methyl ester 95 (0.03 g, 0.07 mmol) 
and MeI (0.05 ml, 0.84 mmol). The crude product was purified by preparative layer 
chromatography (eluent: toluene/EtOAc, 9:1) followed by crystallization in methanol to 
provide the title compound in 90 % yield as white needles. 
Rf = 0.40 (toluene/EtOAc = 9:1) 
m.p. = 102-103 °C  
 
1H-NMR (300 MHz, CDCl3): d = 7.48 (m, 3J (H-16, H-17) = 8.0 Hz, 2H, H-16), 7.41 (t, 1H, 
H-18), 7.39 (d, 3J (H-17, H-16) = 8.0 Hz, 2H, H-17), 6.74 (d, 3J (H-12, H-11) = 9.0 Hz, 2H, 
H-12), 6.64 (d, 3J (H-11, H-12) = 9.0 Hz, 2H, H-11), 6.30 (s, 1H, H-6), 3.73 (s, 3H, H-14), 
3.61 (s, 3H, H-19), 3.53 (s, 3H, H-20), 3.47 (s, 3H, H-8), 3.17 (s, 3H, H-9). 
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13C-NMR (75 MHz, CDCl3): d = 166.27 (C-7), 153.21 (C-5), 152.28 (C-13), 148.56 (C-2),  
142.59 (C-10), 140.12 (C-3), 135.65 (C-1), 133.65 (C-16), 132.62 (C-15), 129.57 (C-17), 
128.49 (C-18), 122.00 (C-4), 115.31 (C-11*), 114.34 (C-12*), 109.31 (C-6), 60.78 (C-20), 
56.06 (C-19), 55.72 (C-14), 52.04 (C-8), 38.99 (C-9).   
* These assignments are interchangeable. 
 
EI-MS (70eV): m/z (%) = 439 (100) [M+], 424 (38) [M+ -CH3], 378 (25) [M+ -OCH3, -
2CH3], 149 (97) [C8H5O3]. 
 
HR-EI-MS: m/z (%) = 439.1444 (M+, calcd 439.1453 for C24H25NO5S). 
 
2-Benzyloxy-3,6-dimetoxy-4-phenyl sulfanyl-benzoic acid methyl ester 
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Alkylated compound 96b was synthesized according to GWP2 starting from hydroquinone 95 
(0.03 g, 0.11 mmol) and MeI (0.08 ml, 1.21 mmol). The crude product was purified by 
preparative layer chromatography on Merck silica gel (60 F254) plates (eluent: PEE/EtOAc, 
8:2) followed by crystallization in MeOH to provide the title compound in 96 % yield as 
white needles. 
Rf = 0.46 (PEE/EtOAc = 8:2) 
m.p. = 93-94 °C 
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1H-NMR (300 MHz, CDCl3): d = 7.47-7.37 (m, 10H, H-11, H-12, H-13, H-15, H-16, H-17), 
6.19 (s, 1H, H-6), 5.10 (d, 2H, H-9), 3.85 (s, 3H, H-18), 3.79 (s, 3H, H-8), 3.53 (s, 3H, H-19). 
 
13C-NMR (100 MHz, CDCl3): d = 107.14 (C-6), 165.97 (C-7), 152.79 (C-5), 149.75 (C-3), 
144.23 (C-2), 137.02 (C-10), 135.0 (C-1), 133.50 (C-15), 130.31 (C-14), 129.50 (C-12, C-16), 
128.40, 128.20 (C-13, C-17), 117.23 (C-4), 128.50 (C-11), 76.68 (C-9), 60.9 (C-19), 56.1 (C-
18), 52.50 (C-8).    
 
EI-MS (70 eV): m/z (%) = 410 (97) [M+], 379 (8) [M+ -OCH3], 269 (95) [M+ -SHC6H5, -
OCH3], 91 (100) [M+ -CH2C6H5]. 
 
HR-EI-MS: m/z (%) = 410.1188 (M+, calcd 410.1149 for C23H22O5S). 
 
2-Butoxy-3,6-dimethoxy-4-phenyl sulfanyl-benzoic acid methyl ester  
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96c 
 
Compound 96c was synthesized according to GWP2 starting from hydroquinone 95 (0.02 g, 
0.06 mmol) and MeI (0.04 ml, 0.74 mmol) to provide the title compound in a 100 % yield as 
yellow oil. 
Rf = 0.72 (hexane/EtOAc = 8:2) 
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1H-NMR (300 MHz, CDCl3): d = 7.49-7.33 (m, 5H, H-14, H-15, H-16), 6.15 (s, 1H, H-6), 
4.11 (t, 2H, H-9), 3.85 (s, 3H, H-8), 3.81 (s, 3H, H-17), 3.52 (s, 3H, H-18), 1.72-1.62 (m, 2H, 
H-10), 1.49-1.40 (m, 2H, H-11), 0.95 (t, 3H, H-12). 
 
13C-NMR (75 MHz, CDCl3): d = 166.15 (C-7), 152.71 (C-5), 150.18 (C-3), 144.27 (C-2), 
134.70 (C-1), 133.40 (C-14), 132.88 (C-13), 129.50 (C-16), 128.33 (C-16), 117.28 (C-4), 
106.89 (C-6), 74.17 (C-9), 60.69 (C-17), 56.07 (C-18), 52.41 (C-8), 32.29 (C-10), 19.13 (C-
11), 13.86 (C-12).    
  
EI-MS (70 eV): m/z (%) = 376 (100) [M+], 345 (12) [M+ -OCH3], 288 (71) [M+ -
O(CH2)3CH3], 273 (25) [M+ -O(CH2)3CH3,  -CH3].  
 
HR-EI-MS: m/z (%) = 376.1331 (M+, calcd 376.1344 for C20H24O5S). 
       
2,5-Diacetoxy-3-(acetyl-phenyl-amino)-6-(N-methyl-4`-anisidino)-benzoic acid methyl 
ester 
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100 
 
A mixture of 93b (0.02 g, 0.05 mmol), triethylamine (0.02 ml, 0.15 mmol), acetic anhydride 
(0.01 ml, 0.15 mmol) and (1.00 mg, 8.00 mmol) of DMAP is allowed to stand for 14 h at 24 
°C. Afterwards the reaction mixture was evaporated in vacuum, and the residue was purified 
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by preparative layer chromatography (eluent: CH2Cl2/EtOAc, 9:1) to afford the title 
compound in 90 % as yellow solid. 
Rf = 0.62 (DCM/EtOAc = 9:1) 
m.p. = 74-75 °C 
                                                        
1H-NMR (300 MHz, CDCl3): d = 7.35 (m, 5H, H-18, H-17, H-16), 6.74 (d, 3J (H-12, H-11) = 
9.0 Hz, 2H, H-12), 6.64 (d, 3J (H-11, H-12) = 9.0 Hz, 2H, H-11), 5.29 (s, 1H, H-1), 3.72 (s, 
3H, H-14), 3.51 (s, 3H, H-8), 3.14 (s, 3H, H-9), 2.16 (d, 2H, H-21, H-24), 2.00 (s, 3H, H-20). 
 
 The 13C-NMR could not be analysing because: 
  -   Broad lines at 304 K are due to hindered rotation about the Ph2NCOCH3 bonds. 
  - Heating the solution to 353 K in (CD3)2SO causes faster rotation, more averaging of         
environments and here sharper lines. 
 
EI-MS (70 eV): m/z (%) = 520 (100) [M+], 478 (72) [M+ -COCH3], 462 (18) [M+ -COCH3, -
CH3].  
 
HR-EI-MS: m/z (%) = 520.1856 (M+, calcd 520.1846 for C28H28N2O8). 
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8.1.5   Compounds from Chapter 4 
2,5-Dihydroxybenzoate 
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                                                               106 
 
To a solution of 2,5-dihydroxybenzoic acid (102) (2.00 g, 12.96 mmol) in 80 ml acetone was 
slowly added benzyl chloride (1.73 g, 14.28 mmol) in 8 ml acetone and K2CO3 (1.97 g, 14.28 
mmol). After 12 h of stirring at 70 °C, the suspension was cooled to 20 °C and filtered. The 
solvent was evaporated in vacuo at 40 °C. The residue was dissolved in EtOAc and purified 
by chromatography (eluent: toluene/EtOAc, 9:1) to provide the title compound in 50 % yield 
as colourless crystals. 
Rf = 0.23 (toluene/EtOAc = 9:1) 
 
1H-NMR (600 MHz, CDCl3): d = 10.34 (s, 1H, HO-2), 7.36-7.44 (5H, m, H-10, H-11, H-12), 
7.32 (d, 4J (H-1, H-3) = 2.8 Hz, 1H, H-3), 6.99 (dd, 3J (H-1, H-6) = 8.9 Hz, 4J (H-1, H-3) = 2.8 
Hz, 1H, H-1), 6.88 (d, 3J (H-1, H-6) = 8.9 Hz, 1H, H-6), 5.36 (s, 2H, H-8). 
 
13C-NMR (151 MHz, CDCl3): d = 169.51 (C-7), 156.1 (C-5), 147.68 (C-2), 135.22 (C-9), 
128.76 (C-10), 128.64 (C-12), 128.35 (C-11), 124.20 (C-1), 118.61 (C-6), 114.80 (C-3), 
112.21 (C-4), 67.13 (C-8).  
 
EI-MS m/z (%) = 244 (100) [M+], 153 (8) [M+ -C6H5CH2], 136 (39) [M+ -C7H4O3], 92 (68) 
[C7H8]. 
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HR-EI-MS: m/z (%) = 244.0733 (M+, calcd 244.0735 for C14H12O4). 
 
The spectroscopic data is in agreement with the assigned structure and those reported by 
Cavallito and Buck.66 
 
2-Benzyloxycarbonyl-1,4-benzoquinone  
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To a solution of 2,5-dihydroxybenzoate (0.02 g, 0.08 mmol) in 0.50 ml methanol was added 
in one portion DDQ (21.48 g, 0.08 mmol). After being stirred at room temperature overnight, 
the reaction solution was evaporated under reduced pressure and the residue was purified by 
preparative layer chromatography (eluent: toluene/EtOAc, 9:1) to provide the title compound 
in 10 % yield. 
Rf = 0.88 (toluene/EtOAc = 9:1) 
 
1H-NMR (300 MHz, CDCl3): d = 7.40-7.31 (m, 5H, H-10, H-11, H-12), 6.70 (d, 3J (H-6, H-
1) = 10.2 Hz, 3J (H-6, H-1) = 10.2 Hz, 2H, H-1, H-6), 5.34 (s, 2H, H-8) 3.92 (s, 3H, H-13). 
 
13C-NMR (75 MHz, CDCl3): d = 184.51 (C-2), 182.01 (C-5), 163.47 (C-7), 153.61 (C-3), 
136.40 (C-6), 134.68 (C-1), 128.15 (C-9), 127.89-128.72 (C-10, C-11, C-12), 118.84 (C-4), 
68.15 (C-8), 59.4 (C-13).  
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ESI-MS: m/z (%) =  295 (100) [M+ + Na], 273 (10) [M+ + H]. 
2,5-Dimethoxy-N-phenyl-benzamide68 
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                                                                    115 
 
 
Oxalyl chloride (0.55 ml, 6.26 mmol) was added dropwise to a stirred suspension of 2,5-
dimethoxybenzoic acid (0.87 g, 4.84 mmol) in 4 ml toluene and drops of DMF. As the 
reaction progressed, the acid gradually dissolved gave a clear-yellow solution. After 2.5 h, the 
volatiles were removed on the rotary evaporator to give the title product as pale-yellow oil, 
which was used immediately in the next step without further purification. 
 
2,5-Dimethoxy-N-phenyl-benzamide 
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To a solution of 115 (0.86 g, 4.30 mmol) in 20 ml acetonitrile was added aniline (0.33 ml, 
4.30 mmol) and K2CO3 (0.77 g, 5.60 mmol). After being stirred at room temperature 
overnight, the reaction solvent was evaporated and the residue redissolved in ether and 
washed with 1N NaOH solution. The organic phase was evaporated and the residue 
recrystallized from ether to give the title product in 53 % yield as white crystals. 
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Rf  = 0.11 (DCM) 
m.p. = 96-97 °C  
 
1H-NMR (300 MHz, CDCl3): d = 9.95 (s, 1H, NH), 7.88 (d, 4J(H-1, H-3) = 3.3 Hz, 1H, H-3), 
7.71 (d, 3J(H-9, H-10) = 8.5 Hz, 2H, H-9), 7.37 (t, 3J(H-10, H-9) = 8.5 Hz, 2H, H-10), 7.14 (t, 
1H, H-11), 7.09 (dd, 3J(H-1, H-6) = 8.8 Hz, 1H, H-1), 6.98 (d, 3J(H-6, H-1) = 8.8 Hz, 1H, H-
6), 4.00 (s, 3H, H-13), 3.85 (t, 3H, H-12). 
 
13C-NMR (75 MHz, CDCl3): d = 162.99 (C-7), 154.26 (C-2), 152.56 (C-5), 138.44 (C-8), 
129.03 (C-10), 124.21 (C-11), 122.47 (C-4), 120.44 (C-9), 119.98 (C-1), 115.69 (C-3), 113.42 
(C-6), 56.95 (C-12), 55.90 (C-13). 
 
ESI-MS: m/z (%) = 280 [M+ + Na], 258 [M+ + H]. 
 
HR-ESI-MS: m/z (%) = 258.1140 (M+ + H, calcd 258.1130 for C15H16NO3). 
 
The spectroscopic data is in good agreement with the assigned structure and those reported by 
Bäckwall et al. 59 
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2,5-Dihydroxy-N-phenyl-benzamide 
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To a cooled (-60 °C) solution of 2,5-Dimethoxy-N-phenyl-benzamide (0.17 g, 0.66 mmol) 
(120) in 1 ml dry DCM under N2 was added BBr3 (0.25 ml, 0.26 mmol). The reaction mixture 
was stirred for 30 minutes at –60 °C, followed by stirring 4 h at room temperature. Then the 
excess of BBr3 was neutralized with MeOH, the solvent was evaporated, the residue 
redissolved in EtOAc and extracted with saturated solution of NaHCO3. Then the organic 
phase was evaporated and the residue purified by chromatography (eluent DCM / MeOH, 9:1) 
in 96 % yield as white solid. 
Rf = 0.49 (DCM/MeOH = 9:1) 
m.p. = 162-163 °C 
 
1H-NMR (400 MHz, CD3OD): d = 11.34 (OH), 7.83 (NH), 7.71 (d, 3J(H-9, H-10) = 8.5 Hz, 
2H, H-9), 7.42 (d, 4J(H-3, H-1) = 4.0 Hz, 1H, H-3), 7.38 (t, 3J(H-10, H-9) = 8.5 Hz, 2H, H-
10), 7.20 (t, 1H, H-11), 6.98 (dd, 4J(H-1, H-3) = 4.0 Hz, 3J (H-1, H-6) = 10.4 Hz, 1H, H-1), 
6.87 (d, 3J(H-6, H-1) = 10.4 Hz, 1H, H-6). 
 
13C-NMR (100 MHz, CD3OD): d = 168.02 (C-7), 152.64 (C-5), 151.30 (C-2), 139.38 (C-8), 
129.89 (C-10), 125.64 (C-11), 122.43 (C-1), 122.31 (C-9), 118.99 (C-4), 118.92 (C-6), 115.76 
(C-3). 
 
ESI-MS: m/z (%) = 252 [M+ + Na], 230 [M+ + H]. 
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HR-ESI-MS: m/z (%) = 230.0816 (M+ + H, calcd 230.0817 for C13H12NO3). 
 
The spectroscopic data is in agreement with the assigned structure and those reported by 
Brimble et al.76 
                                                                                                                                                                                                                                               
8.1.6   Compounds from Chapter 5 
N-(tert-Butoxycarbonyl)-N-methylaminophenol 
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To a solution of N-methylaminophenol (1.00 g, 8.13 mmol) in 25 ml dioxane/water (2:1) was 
added di-tert-butyldicarbonate (1.77 g, 8.13 mmol) in two portions followed by stirring at 
room temperature 4-5 h. Dioxane was then removed in vacuum, the residue was cooled to 0 
°C, and 20 ml EtOAc was added. The solution was acidified to pH 2-3 with KHSO4 and 
extracted three times with EtOAc. The solvent was evaporated under reduced pressure to give 
the title compound in 100 % yield as brown solid. 
m.p. = 132-133 °C 
 
1H-NMR (300 MHz, (CD3)2SO): d = 9.32 (s, 1H, HO-1), 7.17 (d, 3J (H-3, H-2) = 8.9 Hz, 2H, 
H-3), 6.72 (d, 3J (H-2, H-3) = 8.9 Hz, 2H, H-2), 3.14 (s, 3H, H-5), 1.42 (s, 9H, H-8, H-9, H-
10).  
 
13C-NMR (75 MHz, (CD3)2SO): d = 154.94 (C-6), 154.08 (C-1), 134.97 (C-4), 126.78 (C-3), 
114.97 (C-2), 78.85 (C-7), 37.38 (C-5), 27.92 (C-8, C-9, C-10).  
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ESI-MS: m/z (%) = 469 [M+ + Na], 246 [M+ + Na], 224 [M+ + H]. 
 
HR-EI-MS: m/z (%) = 223.1195 (M+, calcd 223.1208 for C12H17NO3). 
 
The spectroscopic data is in agreement with the assigned structure and those reported by 
Fahrey et al.73 
 
Synthesis of (4-benzyloxypolystyrene-phenyl)-methyl amine 
 
O NH
CH3  
130 
 
To a solution of N-(tert-Butoxycarbonyl)-N-methylaminophenol (129) (10 equiv., 1.25 mmol, 
0.28 g) in 1 ml dry DMF was added carefully NaH (10 equiv., 1.25 mmol, 0.03 g) washed 
free of petroleum oil. This slurry was added to the Merrifield resin (0.10 g, 1.25 mmol/g) 
together with KI (1 equiv., 0.125 mmol, 0.02 g). The reaction mixture was stirred gently 
overnight at 60 °C. At the end of this time, the solution was filtered off and the resin washed 
with DMF, DCM, MeOH, followed by Boc deprotection with 50 % TFA/DCM for 15-20 
minutes and washing with DMF, DCM, triethylamine in DCM (1:1), MeOH and DCM to 
afford resin (130) in 93 % yield. 
 
Loading was determined from the chlorine left unreacted on the resin: Boc protected amino 
resin (0.10 g, 0.12 mmol) was heated with pyridine (2 ml) in boiling water for 60 min. The 
solution with the resin was then transferred to an Erlenmeyer flask with 50 ml of 20 % acetic 
acid. A Volhard titration for chloride was carried out by addition of ferric amoniumsulfate 
indicator (3 drops), concentrated nitric acid (5 ml), 0.1 N AgNO3 (5 ml), and toluene (3 ml), 
followed by back-titration with 0.1 N KSCN.74 
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% Cl- = 3.545 (V1N1-V2N2)/m 
 
V1 = the added amount of silver nitrate solution (ml) 
N1 = the normality of silver nitrate solution  
V2 = the added amount of ammonium thiocyanate solution during the titration (ml) 
N2 = the normality of the ammonium thiocyanate solution 
m = the weight of the sample (g) 
 
2-[(4-Benzyloxypolystyrene-phenyl)-methyl-amino]-3,6-dioxo-cyclohexa-1,4-diene-
carboxylic acid methyl ester 
 
O N
CH3 O
OO
H3CO
 
 
132 
 
To swollen resin 130 (0.10 g, 0.125 mmol) was added a solution of 1,4-benzoquinone 39 (6 
equiv., 0.75 mmol, 0.12 g) followed by stirring overnight at room temperature. Afterwards the 
solution was filtered off and the dark violet resin was washed with DCM. Then DDQ (2 
equiv., 0.25 mmol, 0.06 g) in 1 ml DCM was added to swollen resin. The mixture was stirred 
overnight at room temperature. At the end of this time the solution was filtered and the resin 
was washed with DCM to provide violet resin 132. 
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7-[(4-Hydroxy-phenyl)-methyl-amino]-5,8-dioxo-1,4,4a,5,8,8a-hexahydro-1,4-methano-
naphtalene-6-carboxylic acid methyl ester  
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                                                                 135 
                                                                             
To swollen resin 132 (0.10 g, 0.125 mmol) was added a solution of freshly cracked 
cyclopentadiene (40 equiv., 5 mmol, 0.30 g) in 1 ml toluene. The reaction mixture was stirred 
overnight at room temperature. At the end of this time the solution was filtered off and the 
orange resin was washed with DCM, MeOH and ether followed by drying to provide the resin 
135. Cleavage according to GWP8 afforded the title compound in a 25 % yield as orange solid 
after purification by preparative layer chromatography (eluent: DCM/EtOAc, 9:1). 
Rf   = 0.28 (DCM/Ether = 7:3) 
m.p. = 161-162 °C 
 
1H-NMR (400 MHz, CDCl3): d = 6.94 (d, 3J (H-11, H-12) = 9.0 Hz, 2H, H-11), 6.72 (d, 3J 
(H-12, H-11) = 9.1 Hz, 2H, H-12), 6.22 (dd, 3J (H-15, H-16, H-14) = 5.7 Hz, 1H, H-15), 6.12 
(dd, 3J (H-16, H-15, H-17) = 5.7 Hz, 1H, H-16), 5.60 (s, 1H, OH), 3.50 (m, 1H, H-14), 3.35 
(m, 1H, H-17), 3.41 (s, 3H, H-8), 3.36 (dd, 3J (H-6, H-17) = 9.2 Hz, 3J (H-6, H-1) = 3.8 Hz, 
1H, H-6), 3.28 (s, 3H, H-9), 3.25 (dd, 3J (H-1, H-14) = 9.2 Hz, 3J (H-1, H-6) = 3.8 Hz, 1H, H-
1), 1.55 (t, 1H, H-18a), 1.40 (t, 1H, H-18b).   
 
13C-NMR (100 MHz, CDCl3): d = 196.98 (C-2*), 193.30 (C-5*), 166.69 (C-7), 155.41 (C-3),  
154.78 (C-13), 138.34 (C-10), 136.76 (C-15**), 135.05 (C-16**), 127.12 (C-11), 118.41 (C-
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4), 116.18 (C-12), 52.00 (C-8), 50.27 (C-6), 49.96 (C-1), 48.80 (C-18),  47.75 (C-14***),  
47.35 (C-17***), 44.13 (C-9). 
*, **, *** These assignments are interchangeable. 
 
ESI-MS (70 eV): m/z (%) = 355 (25) [M+ + 2H], 354 (100) [M+ + H], 353 (4) [M+]. 
 
HR-ESI-MS: m/z (%) = 354.1340 (M+ + H, calcd 353.1341 for C20H20NO5).  
 
2-[(Pyrrolidine-2-carbonyl)-amino]-propionic acid benzylpolystyrene ester76 
 
OOC CH
CH3
NHCO
NH
 
  
 141 
 
To the swollen N-Ala functionalized Merrifield resin synthesized according to GWP9 (0.10 g, 
0.125 mmol, 1 equiv.) was added a solution of N-Fmoc-Pro-OH (138) (0.62 mmol, 0.21 g), 
TBTU (0.62 mmol, 0.20 g) and DIPEA (1.25 mmol, 0.217 ml) in 1ml DMF. After stirring for 
3 h at room temperature, the solution was filtered off, the resin washed with DMF, DCM, 
MeOH and dried under high vacuum overnight to provide resin 139 which was then Fmoc 
deprotected with 20 % piperidine in DMF for 15-20 minutes followed by washing with DCM 
and MeOH to provide the title resin 1.14 mmol/g (the loading was determined according to 
GWP10). 
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3a-(1-Carboxy-ethylcarbamoyl)-7-hydroxy-1,2,3,3a-tetrahydro-benzo [d] pyrrolo [2,1-b] 
oxazole-8-carboxylic acid methyl ester 
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A solution of 2-methoxycarbonyl-1,4-benzoquinone 39 (6 equiv., 0.75 mmol, 0.12 g) in 1 ml 
DCM was added to the swollen resin 141 (0.10 g, 0.125 mmol). The mixture was stirred 
overnight at room temperature. Afterwards the solution was filtered off and the resin was 
washed with DMF, DCM, MeOH followed by drying overnight under high vacuum to afford 
the purple resin 142. Cleavage according to GWP8 afforded the title compound in a 50 % 
yield as yellow-brown solid. 
m.p. = 74-75 °C 
Rf  = 0.38 (DCM/MeOH = 8:2) 
 
1H-NMR (300 MHz, CDCl3): d = 10.60, 10.55 (s, 1H, HO-5), 7.59, 7.50 (d, 1H, NH), 6.89, 
6.87 (d, 3J (H-1, H-6) = 8.7 Hz, 1H, H-1), 6.51, 6.49 (d, 3J (H-6, H-1) = 8.7 Hz, 1H, H-6), 
5.57 (s, 1H, HO-16), 4.58-4.46 (m, 1H, H-14), 3.97 (s, 3H, H-8), 3.70, 3.21 (m, 1H, H-10), 
2.44, 2.35 (m, 2H, H-12), 2.06, 1.94 (m, 2H, H-11), 1.44, 1.41 (d, 3H, H-15). 
 
 13C-NMR (75 MHz, CDCl3): d = 175.93, 175.85 (C-16), 170.61, 170.08 (C-13), 169.47, 
169.42 (C-7), 156.71, 156.61 (C-5), 144.35, 144.26 (C-2), 140.32, 140.13 (C-3), 115.85, 
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115.03 (C-1), 110.78, 110.53 (C-6), 108.52, 108.42 (C-9), 102.75 (C-4), 59.54, 58.32 (C-10), 
52.98, 52.53 (C-8), 48.15, 48.11 (C-14), 36.00, 35.85 (C-12), 24.50, 24.38 (C-11), 17.97, 
17.93 (C-15). 
 
ESI-MS: m/z (%) = 723 [2M+ + Na], 373 [M+ + Na], 351 [M+ + H].  
 
HR-EI-MS: m/z (%) = 350.1092 (M+, calcd 350.1114 for C16H18N2O7).  
 
3-[(Pyrrolidine-2-carbonyl)-amino]-propionic acid benzylpolystyrene ester 76 
 
OOC (CH2)2 NHOC
NH
 
141 
 
To the swollen N-b-Ala functionalised Merrifield resin synthesized according to GWP9 (0.10 
g, 0.125 mmol, 1 equiv.) was added a mixture of N-Fmoc-L-Pro and N-Fmoc-D-Pro (1:1), 
(0.62 mmol, 0.21 g), TBTU (0.62 mmol, 0.20 g) and DIPEA (1.25 mmol, 0.217 ml) in 1 ml 
DMF. After stirring for 3 h at room temperature, the solution was filtered off, the resin 
washed with DMF, DCM, MeOH and dried under high vacuum overnight to provide resin 
139 which was then Fmoc deprotected with 20 % piperidine in DMF for 15-20 minutes 
followed by washing with DCM and MeOH to provide the title resin 1.12 mmol/g (the 
loading was determined according to GWP10). 
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3a-(2-Carboxy-ethylcarbamoyl)-7-hydroxy-1,2,3,3a-tetrahydro-benzo [d] pyrrolo [2,1-b] 
oxazole-8-carboxylic acid methyl ester 
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A solution of 2-methoxycarbonyl-1,4-benzoquinone 39 (6 equiv., 0.75 mmol, 0.12 g) in 1ml 
DCM was added to the swollen resin 141 (0.10 g, 0.125 mmol). The mixture was stirred 
overnight at room temperature. Afterwards the solution was filtered off and the resin was 
washed with DMF, DCM, MeOH followed by drying overnight under high vacuum to afford 
the purple resin 143. Cleavage according to GWP8 afforded the title compound in 40-50% 
yield as yellow-brown solid. 
 
1H-NMR (300 MHz, CDCl3): d = 10.58 (s, 1H, OH), 7.58 (t, 1H, NH), 6.86 (d, 3J (H-1, H-6) 
= 8.8 Hz, 1H, H-1), 6.46 (d, 3J (H-6, H-1) = 8.8 Hz, 1H, H-6), 3.96 (s, 3H, H-8), 3.65 (ddd, 2J 
(H-10A, H-10B) = 11.0 Hz, 3J (H-10A, H-11) = 8.0, 6.0 Hz, 1H, H-10A), 3.50 (dt, 3J (H-14, 
NH) = 6), 3J (H-14, H-15) = 6.1 Hz, 2H, H-14), 3.19 (ddd, 2J (H-10A, H-10B) = 11 Hz, 3J (H-
10B, H-11) = 7.0, 4.5 Hz, 1H, H-10B), 2.55 (t, 3J (H-15, H-14) = 6.0 Hz, 2H, H-15), 2.47 
(ddd, 2J (H-12A, H-12B) = 13.5 Hz, 3J (H-12A, H-11) = 9.0, 7.0 Hz, 1H, H-12A), 2.34 (ddd, 
2J (H-12B, H-12A) = 13.5 Hz, 3J (H-12B, H-11) = 7.5, 5.5 Hz), 1H, H-12B), 1.95 (m, 2H, H-
11).   
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 13C-NMR (75 MHz, CDCl3): d = 176.69 (C-16), 170.75 (C-13), 169.48 (C-7), 156.57 (C-5), 
144.42 (C-2), 140.32 (C-3), 114.86 (C-1), 110.54 (C-6), 108.69 (C-9), 102.74 (C-4), 58.23 
(C-10), 52.51 (C-8), 35.72 (C-12), 34.60 (C-14), 33.54 (C-15), 24.47 (C-11). 
 
ESI-MS: m/z (%) = 373 [M+ + Na], 351 [M+ + H].  
 
HR-ESI-MS: m/z (%) = 351.0930 (M+ + H calcd 351.1192 for C16H19N2O7). 
 
 (4-Benzylpolystyrene-benzyl)-phenyl amine80 
 
O NH
 
149 
 
To a suspension of bromo-Wang resin (148) (0.50 g, 1.60 mmol/g) in 11 ml dried DCM was 
added aniline (0.73 ml, 8.00 mmol). The suspension was gently stirred at room temperature 
overnight. Then the mixture was transferred to a syringe reactor and washed successively with 
THF-H2O (3:2, 3x10 ml), H2O (3x10 ml), THF (3x10 ml), DCM (3x10 ml), to give the title 
resin 149. 
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5-Hydroxy-2-(4-hydroxy-phenyl)-3-phenyl-2,3-dihydro-benzooxazole-4-carboxylic acid  
methyl ester 
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To the swollen amino resin 149 (0.50 g, 1.60 mmol/g) was added a solution of 2-
methoxycarbonyl-1,4-benzoquinone (0.72 mmol, 4.36 mmol) in 3 ml dried toluene followed 
by stirring at room temperature overnight. Then, the resin was filtered off and washed with 
DCM followed by drying under reduced pressure. The resin was then treated with TMSOTf 
(10 equiv., 1.45 ml, 8.00 mmol) in 27 ml dry DCM at room temperature for 3 h. At the end of 
this time, a saturated aqueous solution of NaHCO3 was added. The aqueous layer was 
extracted with DCM. The combined organic layer was washed with aqueous NaCl and dried 
over MgSO4. After removal of the solvent, the residue was purified by preparative layer 
chromatography (PLC) on Merck silica gel (60 F254) plates (eluent: toluene/EtOAc, 9:1) to 
provide the title compound in 1.3 % yield as yellow oil. 
Rf  = 0.40 (toluene/EtOAc = 9:1) 
 
1H-NMR (300 MHz, CD3OD): d = 10.13 (s, 1H, OH-5), 7.45 (d, 3J (H-15, H-16) = 8.7 Hz, 
2H, H-15), 7.22 (t, 3J (H-12, H-11) = 7.9 Hz, 2H, H-12), 7.07 (t, 1H, H-13), 6.89-6.5 (m, 5H, 
H-11, H-16, H-1), 6.51 (s, 1H, H-9), 6.45 (d, 3J (H-6, H-1) = 8.7 Hz, 1H, H-6), 3.27 (s, 3H, H-
8). 
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13C-NMR (75 MHz, CD3OD): d = 169.16 (C-7), 156.64 (C-17), 155.30 (C-5), 146.97 (C-10), 
144.59 (C-2), 135.44 (C-3), 131.90 (C-14), 129.14 (C-12), 128.60 (C-15), 124.46 (C-13), 
120.56 (C-11), 115.62 (C-16), 114.65 (C-1), 108.79 (C-6), 102.10 (C-9), 51.25 (C-8).  
 
ESI-MS: m/z (%) = 386 [M+ + Na], 364 [M+ + H]. 
  
HR-ESI-MS: m/z (%) = 364.1170 (M+ + H, calcd 364.1184 for C21H18NO5). 
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8.2   Biological Materials and Methods 
 
8.2.1   Materials 
Laboratory equipment and material 
Pipettes: Glass pipettes sterilized at 180 °C, 4 h. 
Cell culture flasks: Tissue culture flask, 50 ml, polystyrene (Becton Dickinson, U.S.A) 
96-well plate: Microtest 96 (Becton Dickinson, U.S.A) 
Microscope: Axiophot 35M (Zeiss, Jena, Germany) 
The UV-absorption measurements for Cell Proliferation assay were run on a Titertek 
Multiscan MCC/340 
Sarstedt: Petri dishes 
Nalge Nunc: Four well plates 
 
Chemicals 
All chemicals were purchased from the following suppliers and used without further 
purification: 
Cambrex: Dubelco`s MEM; Fetal bovine serum (FBS) 
Marcor: caseine peptone 
Difco: proteose peptone; yeast extract; malt extract 
Merck: meat extract; NaOH 
Roth: HEPES; HCl 
Sigma: MTT solution  
J.T.Baker: isopropanol; acetone; methanol 
Sigma: DAPI 
GIBCO: trypsin, PBS 
 
  126
Cell lines 
L-929 mouse fibroblasts (ACC2) and PtK2 (ATCC CCL-56) cell line were provided by 
Deutsche Sammlung von Mikroorganisme und Zellkulturen and American Type Culture 
Collection. 
 
Antibodies 
Affinity BioReagents: monoclonal antibody against GRP-94; polyclonal antibody against ?-
tubulin 
Babco: goat anti-rat immunoglobulin G antibody conjugated with Alexa Fluor 488; goat anti-
rabbit IgG antibody conjugated with Alexa Fluor 594. 
 
Media and Reagents 
Growth Medium (EBS) 
5 g/l caseine peptone 
5 g/l proteose peptone 
1 g/l meat extract 
1 g/l yeast extract 
10 g/l HEPES, adjust pH 7.0 with 5M NaOH 
 
Growth Medium 90 
30 g/l malt extract 
3 g/l caseine peptone, adjust pH 5.6 with 1M HCl 
 
Staining Reagent 
Azur B 
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8.2.2   Methods 
Note: all procedures from this point on were performed using sterile technique. 
 
Agar diffusion assay 
Bacteria to be tested (Staphylococcus aureus, Mycobacterium phlei, Micrococcus luteus, 
E. coli tolC, Pseudomonas aeruginosa, Klebsiella pneumoniae) were grown in standard EBS 
medium (5 g/l caseine peptone, 5 g/l proteose peptone, 1 g/l meat extract, 1 g/l yeast extract, 
10 g/l HEPES, pH 7.0) overnight. An aliquot of the cultures were seeded into molten EBS 
agar (1.5 %) medium to give an O.D. of 0.01. 15-ml aliquots of the still liquid medium were 
poured into Petri dishes. When the medium had solidified a paper disc of 6 mm diameter 
soaked with 20 µl of the compound solution to be tested were placed on the agar and the Petri 
dishes were incubated at 30 °C.  
Assays with fungi were done in same way except that they were grown in medium 90 (30g/l 
malt extract, 3 g/l caseine peptone, pH 5.6). Yeasts (Candida albicans, Hansenula anomala, 
Saccharomyces cerevisiae) were seeded into the agar medium to give an O.D. of 0.1. With 
hyphal fungi (Aspergillus fumigatus, Botrytis cinerea, Pythium debaryanum), conidia 
collected from grown agar cultures were seeded into the assay agar plates according to 
experience.  
The diameter of inhibition zones were measured after 1-2 days and given as a parameter for 
the antibiotic activity of a compound. 
 
Minimal inhibitory concentration (MIC) test 
120 ml of Saccharomyces cerevisiae culture, which was diluted to an O.D. of 0.15 was added 
to 60 µL of serial dilutions of the compounds in a 96-well microplate and incubated at 30 °C 
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overnight. The O.D. of the wells of the microplate was measured at 595 nm by a plate reader. 
The concentration range tested was normally 370 µg/ml down to 6 ng/ml. 
 
Cytotoxicity assay 
L-929 mouse fibroblasts cells were grown for 6-8 days at 37 °C, 10 % CO2 in Dulbecco`s 
modified Eagle`s medium/high glucose (DMEM) supplemented with 10% (v/v) fetal calf 
serum and glutamine. The medium was removed and cells washed with EBBS twice. Then the 
cells were detached from there substrate by incubation with trypsine for 5-10 min and 
resuspended in new medium to a final density of 50.000 cells/ml. The cells (120 µl) were 
added to a serial dilution of the test compounds in 96-well plates (6000 cells/well). After 5 
days of incubation, growth was observed under the microscope and determined by an MTT 
assay. The normal concentration of the compounds tested ranged from 370 µg/ml down to 6 
ng/ml. 
 
MTT assay 
A solution of MTT (5mg/ml) was added to 96-well plates (20 ml/well) and incubated at 37 °C, 
10 % CO2 for 2 h. Then the plates were centrifuged, washed with PBS (100 ml/well), and the 
precipitated formazan crystals dissolved with a solution of 0.04N HCl in isopropanol (100 
ml/well). After shaking the plates for 15 min the absorbance values measured at 595 nm in a 
microplate reader were taken as parameters of growth and vitality of the cells. 
 
Cell staining and fluorescence labelling 
PtK2 cells were grown on glass cover slips (13 mm diameter) in four well plates to semi-
confluent density and incubated with the compounds to be tested. At the end of incubation 
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time the supernatant medium was removed and cells were fixed with cold (-20 °C) acetone-
methanol (1:1) for 10 min. For morphological studies cells were stained by azure B. 
For labelling the endoplasmatic reticulum (ER) cells were incubated with a primary 
monoclonal antibody against GRP-94 (1:1000; Affinity BioReagents, Golden, U.S.A), and a 
secondary goat anti-rat immunoglobulin G antibody conjugated with Alexa Fluor 488 (1 
µg/ml; Molecular Probes, Leiden, The Netherlands) at 37 °C, each for 1 hour.  
For labelling the centrosomes, we used polyclonal antibodies against ?-tubulin (Babco) and a 
secondary goat anti-rabit IgG antibody conjugated with Alexa Fluor 594 (Molecular Probes).  
Cells were rinsed with phosphate-buffered saline (GIBCOBRL, Eggenstein, Germany) 
between two incubations. 
The nuclei were stained with DAPI (4’,6-Diamino-2-phenylindole; 1µg/ml). 
After staining the coverslips were mounted using Prolong Antifade (Molecular Probes), and 
examined with a Zeiss Axiophot fluorescence microscope (Carl Zeiss, Jena, Germany) using 
appropriate filter sets. 
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Abbreviations 
11-b-HSD-1     11-b-Hydroxysteroid dihydrogenase type 1   
11-b-HSD-2    11-b-Hydroxysteroid dihydrogenase type 2   
Ac2O                 Acetic anhydride 
Boc                    Tert-butyl carboxycarbonyl 
Cdc25A             Cell cycle-dependant kinase A 
CDK                  Cyclin-dependant kinase 
DCM                  Dichlormethane 
DDQ                  2,3-Dichloro-5,6-dicyano-p-benzoquinone 
DIPEA               N,N-Diisopropylethylamine 
DMAP               4-Dimethylaminopyridine 
DMF                 N,N-Dimethylformamide 
EtOAc              Ethyl acetate 
EI                     Electron impact 
ESI                   Electron spray ionization 
Fmoc                9-Fluorenylmethyloxycarbonyl 
IC50                 50% inhibitory concentration 
MAP                Mitogen activated protein 
MEK               Mitogen activating potein kinase 
MeOH             Methanol 
MIC                 Minimal inhibition concentration 
MS                   Mass spectrum 
NMR               Nuclear magnetic resonance 
PEE                 Petroleum ether 
PLC                 Preparative layer chromatography 
Rf                    Retention factor 
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RT                   Room temperature 
TBTU              O-(Benzotriazol-1-yl)-N,N,N`,N`-tetramethyluronium tetrafluoroborate 
TEA                Trietyl amine 
TFA                 Trifluoro acetic acid 
THF                Tetrahydrofuran 
TMSOTf         Trimethylsilyl triflate 
VHR               Vaccinia virus H1-related phosphatase 
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Zusammenfassung 
 von 
Valentina Wachter 
aus  
Baia-Mare, Rumänien 
 
„Kombinatorische Synthese von Bibliotheken niedermolekularer 
Verbindungen um das p-Benzochinon-Grundgerüst“ 
 
 
Die aus Chinon-Grundgerüst abgeleitete Naturstoffe sind für ihre zahlreichen biologischen 
Äktivitäten bekannt. Aus dem Grund stellt das 2-Methoxycarbonyl-1,4-benzochinon ein 
geeignetes Templat für die Synthese von Bibliotheken niedermolekularer Verbindungen für 
die chemisch genetischen Studien dar. 
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Abb. 1: Struktur von  2-Methoxycarbonyl-1,4-benzochinon 
 
Das Ziel der vorliegenden Arbeit war die Entwicklung eines effizienten Synthesewegs für die 
Darstellung von p-Benzochinon-Bibliotheken unter Einbezug des Micheal-Addition- 
Konzeptes (siehe Abb. 2). Im ersten Schritt erfolgt die regioselektive Addition von 
verschiedenen Nuckleophilen am Benzequinonering unter Bildung von Hydrochinon als 
Zwischenstufe, welches in einem zweiten Schritt zu  dem entsprechenden Chinon oxidiert 
wird. Unter diesen Reaktionsbedingungen (Oxidation und Reduktion) wurden zahlreiche 
Subtituenten an modifiziebaren Postionen am 1,4-Benzochinonering eingeführt. In einem 
weiteren Schritt wurden die gebildeten Hydochinone bzw. Chinone durch Alkylierung- bzw. 
Aceteylierungsreaktionen modifiziert.   
 
 
Um die Machbarkeit dieser Strategie und das Potenzial des 2-Methoxycarbony-1,4-
benzochinons als Grundgerüst zu demonstrieren, wurden die ersten Benzochinonederivative 
in der Lösung synthetisiert (siehe Abb. 2). 
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Figure 2: Zusammenfassung der Synthese von 2-Methoxycarbonyl-1,4-benzochinone Derivate in Lösun. 
 
 
 
Die biologische Aktivitäten der synthetisierten Benzoquinonederivate wurden anschliessend 
anhand der verschieden biologischen Assays evaluiert. Die Ergebnisse dieser Untersuchungen 
sind in der Tabelle 1 zusammengefasst. 
 
 
Die ersten biologischen Untersuchungen wurden in Form von cytotoxischen Assays 
durchgeführt. In diesen zellbasierten Assays zeigten die Benzochinonderivate 
Cytotoxititätswerte zwischen 7 und 60 μmol. 
 
 
 
 
Tabelle 1. Wachstumsinhibitionsaktivitäten der Verbindungen 96a, 100, 94a, 94b, 96b, 
96c, 94c, 56a, 56b, 56c, 56d, 144 mit kultivierten L-929 Mausfibroblasts. 
Verbindung IC50 
 [µg/ml] [µmol/L] 
56a 2.3 7 
56c 4.5 11 
56d 5.1 14 
94a 7 16 
94b 15 34 
56b 15 36 
100 31 60 
96a >400 no inhibition 
96b >400 no inhibition 
96c 95 231 
94c 54 128 
144 53 151 
 
 
Desweiteren wurden die Wirkunksweise der Benzochinon-Derivate in zahlreichen 
Immunofluorescence Assays getestet. Sie alle zeigten in Zellkernen interessante 
phenotypische Effekte, welche in der Stärke und Details voneinander varierten. Es ist aber 
schwer eine Aussage zu machen, ob diese phenotypischen Effekte aufgrund der 
underschiedlichen Wirkungsweise der untersuchten Verbindungen auftreten. Die 
beobachteten Phenomene scheinen sich zu überlappen und bedürfen daher weiterer 
Untersuchungen. 
 
 
Anschliessend wurden die Benzochinone Derivate auf Ihre bakterizid, antibiotische und 
fungal Aktivitäten in mikrobiologischen Assays getestet. Keine der untersuchten 
Verbindungen  zeigten antibakterielle und antifungal Aktivitäten, lediglich zwei der 
Verbindungen zeigten moderate antibiotische Aktivität (siehe Abb. 3.) 
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Abb. 3: Strukturen der aktiven Verbindungen 56a and 56c. 
 
 
 
Der nächster Schritt war die Implementierung des Michael-Addition Konzeptes an der 
Festphase. Im ersten Schritt der Synthese erfolgt die Addition von Boc-geschützten 
Nucleophilen als Ester bzw. Ether am Merrifield-Harz, welches dann in einem weiteren 
Schritt mit 2-Methoxycarbonyl-1,4-benzochinone weiter funktionalisiert wird. Das hiebei 
entstandene Hydrochinon wird  mith DDQ zum Benzochinon oxidiert. Das resultierende 
monosubstituierte Benzochinon reagiert in einer weiteren Additionreaktion mit zweitem 
Nucleophilen unter Bildung vom disubstituerten Intermediat, welches anschliessend durch 
Alkylierung- bzw. Aceteylierungsreaktionen geschützt wird. Zum Schluss wird das gebildete 
Produkt von der Festphase unter saurer Konditionen mit SnCl4 abgespalten. Mit dieser 
Strategie wurden die ersten Syntheseversuche an der Festphase durchgeführt (siehe Abb. 4) 
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Fig 4:Beispiele für die Synthese von Benzochinonederivate an der Festphase. 
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